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ABSTRACT 
 
 
IN-SITU TISSUE ENGINEERING OF THE INTERVERTEBRAL DISC 
 
 
Pang-ning Teng, MS 
 
 
University of Pittsburgh, 2003 
 
 
 
A possible approach to stimulate proteoglycan and collagen synthesis for treating 
intervertebral disc degeneration (IDD) is introduction of growth factors.  The objective of Part I 
of this study was to screen the effect of human recombinant bone morphogenetic protein (BMP)-
2 and BMP-12 on nucleus pulposus (NP) cells and to investigate the effect of Ad/BMP-12 on NP 
and anulus fibrosus (AF) cells.  Cells were isolated from degenerated human discs and cultured 
in monolayer.  RhBMP-2 (25, 50, 100, 200, 300, ng/ml) and rhBMP-12 (25, 50, 100 ng/ml) 
stimulated NP cells in serumless media (1% ITS) for 2 days.  Ad/BMP-12 (50, 100, 150 MOI) 
transduced NP and AF cells, then pellets (150,000 cells/pellet) were formed and incubated in 
serumless media (1% ITS) for 6 days.   Proteoglycan, collagen, and non-collagenous protein 
synthesis were measured.  RhBMP-2 had a more substantial effect on upregulating matrix 
synthesis than rhBMP-12.  Ad/BMP-12 significantly increased matrix synthesis.  Total DNA 
content was increased pellets stimulated by Ad/BMP-12 when compared to control.  The 
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increase in matrix synthesis was attributed to both an increase in cell number and in matrix 
synthesis per cell.   
Intervertebral disc (IVD) is the largest avascular organ in the body, it has been suggested 
that lack of nutrition may be one of the cause of IDD.  The goals of the second part of this study 
were to develop a rabbit disc organ culture method to study the effect of FBS concentration in 
disc metabolism and to attempt gene therapy in the organ culture.  Twenty-seven rabbit lumber 
intervertebral discs were harvested and cultured for 2 weeks in serumless media (1% ITS) or F-
12/DMEM (5%, 10%, 15% FBS).  NP and AF wet weight, dry weight, % hydration, 
glycosaminoglycans (GAG), DNA, and lactate content were measured.  In 25 discs, 6x106 PFU 
of Ad/lacZ or Ad/Luciferase was injected into the NP 2 days after the culture to determine the 
effect of gene transfer.  Histology and viability staining of 10 discs were used to show cell 
morphology and viability.  Due to low cell viability, we did not observe successful gene transfer 
in the organ culture.  NP and AF lactate content and AF DNA content were significantly higher 
in the 15% FBS group than serumless group.   
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1.0 INTRODUCTION 
 
1.1 Intervertebral Disc Degeneration (IDD) 
 
During the natural aging process, the intervertebral disc undergoes degeneration.1  IDD can be 
described as a number of mechanical and biological changes including water loss from the 
nucleus pulposus, tears within the annulus, disc height loss, disc protrusion, and disc herniation.2  
IDD is a major factor in low back pain, however its etiology and pathophysiology are not well 
understood.3   
In healthy discs, the nucleus region of the disc is rich in proteoglycans, molecules that can 
attract water.  Degenerated discs have less proteoglycans in the nucleus.  This leads to 
dehydration.  The loss of disc height in disc degeneration is due in part to loss of water content.  
These biochemical changes alter the mechanical function of the disc.4,5
Primary disc degeneration is another term to denote the mechanical and biological changes 
in the disc accompanying aging.  Intervertebral discs can also undergo faster changes than the 
natural aging process, such as degeneration in discs adjacent to a long fusion or degeneration in 
discs following annulus injury.  These changes are termed secondary disc degeneration.  Other 
factors associated with secondary disc degeneration include smoking, obesity, and high 
mechanical spinal loads.6,7   
  
1.1.1 Impact of IDD 
 
Back pain causes substantial health and economic impact on the society.  It affects a large 
proportion of the adult population. About 80% of adults will experience at least one episode of 
back pain during adulthood.8  IDD has been implicated as a major factor in low back pain.2  IDD 
first appears in males in their twenties and women in their thirties.  By the age of 30, around 30% 
of the discs show noticeable degenerative changes.9  By the age of 50, 97% of the discs show 
signs of degeneration.1  Back pain is the 2nd most frequent reason for a physician visit, the 3rd 
most frequent reason for a surgical procedure, and 5th most frequent cause of hospitalization.10  It 
can limit one’s physical and social activities due to increased pain and it reduce a person’s 
independence and quality of life.   
Annual costs from back pain are estimated to be more than $50 billion and could be as high 
as $100 billion annually in the United States.11  Direct health costs come from the diagnosis and 
treatment of musculoskeletal diseases and trauma.  The indirect economic losses include work 
day loss, reduced productivity, and activity limitations due to musculoskeletal impairments and 
disability.12  Back pain is the most common cause of activity limitation in persons less than 45 
years of age.13  An annual average of 175.8 million restricted activity days are caused by spine or 
back impairments14.  
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1.1.2 Current Treatment Paradigms for IDD 
 
There is currently no cure for intervertebral disc degeneration.  Primary disc degeneration is a 
consequence of natural aging, therefore viewed as inevitable and unpreventable with the limited 
technology now available. Once the disc begins to degenerate, it is difficult to stop or reverse the 
process with current treatments.  There are conservative treatments and operative or invasive 
treatment.  While primary disc degeneration cannot be prevented, secondary disc degeneration 
may be minimized by decreasing smoking, maintaining healthy body weight, avoiding high 
mechanical spinal loads, and avoiding spinal fusion if possible.    
Some of the more common therapeutic conservative techniques include bed rest or 
controlled physical activity, drug therapy with anti-inflammatory agents, trigger-point injection, 
epidural steroid injection, medication, traction, spinal manipulation, spinal bracing, physical 
therapy, back school, and exercise. 15  Some of these techniques might relieve the symptoms of 
IDD but they do not directly treat the disc.  From the evidence available, controlled physical 
activity appears to be more effective than other conservative treatments. However, the objective 
support of efficacy of these techniques is lacking due to the difficulty in performing prospective 
double-blind studies.16  
The current clinical options for treating IDD are limited and they are highly invasive. 
Operative treatments include chemonucleolysis, discectomy, and spinal fusion. 
Chemonucleolysis is the injection of chymopapain to decrease the intradiscal pressure to release 
nerve root pressure. However the efficacy is questionable and can induce severe complications 
such as paralysis.17  Discectomy involves removing some or all portions of the disc and it usually 
 19
requires additional fusion surgery to restore stability of the spinal segments. Spine fusion is one 
of the most performed spine surgeries.  More than 250,000 fusions are performed each year in 
the US.18  Fusion eliminates the movement across an intervertebral motion segment by bony 
union.19  The goals of these operative treatments are to decompress neural elements, stabilize 
unstable spinal levels, or correct deformity.20  The outcome can vary and it may increase the 
secondary disc degeneration in the adjacent discs.  As with conservative techniques, these 
surgical procedures cannot cure or regenerate the degenerated disc.  Also as with any other 
surgical procedure, there are risks of complications.  There remains a need for less-invasive, 
safer, and more effective treatments for IDD.        
 
 
1.1.3 Potential Future Treatments 
 
 
Scientists are making advancements in developing future treatments for IDD.  Current research 
includes organ transplantation and tissue engineering.  Options for intervertebral disc 
transplantation include autografts, allografts, and xenografts.19  Tissue engineers are also testing 
novel techniques to directly treat the disc by nucleus pulposus implantation, cell implantation, 
matrix substitution, and cell-seeded scaffolds.21,22  Notochordal cells and stem cell are potential 
candidates for cell implantation.23,24  Many tissue engineering techniques can be used in 
conjunction with growth factors or gene therapy.  In-situ tissue engineering methods that are 
under investigation include growth factor and intradiscal gene therapy.      
One possible minimally invasive treatment for disc disease is the introduction of 
therapeutic amounts of growth factor proteins to the disc. Growth factors are extracellular 
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polypeptide-signaling molecules that can stimulate cells to grow or proliferate.  They have been 
tested in animal models and have shown the ability to enhance tissue repair.  In-vitro studies 
have demonstrated that addition of human transforming growth factor TGF-beta 1 to canine disc 
tissue in culture stimulated in-vitro proteoglycan synthesis, suggesting that TGF-beta 1 might be 
useful for the treatment of IDD.25  However, direct injection of growth factors into a disc has the 
limitation of a short half-life.  Disc degeneration is chronic and it appears to require a sustained 
delivery of exogenous growth factors to the disc.  
Gene therapy can potentially provide a mechanism by which intervertebral disc cells 
might produce an encoded-for growth factor (or other gene product) continuously.  There are 
many candidate genes that researchers are testing such as TGF beta-1, IGF-1, PDGF, EGF, OP-
1, and BMP-2.  In-vivo study in a rabbit model of intradiscal gene therapy using adenovirus with 
TFG beta-1 has shown positive results in upregulating matrix synthesis.26  Human disc cells from 
degenerated discs are genetically modifiable in-vitro by adenovirus-mediated gene transfer.27  
One potential clinical application of intradiscal gene therapy would be to inject therapeutic genes 
into a degenerated disc with the intent of regenerating the disc constituents (collagens and 
proteoglycans) to improve biological and mechanical function. Another application, more along 
the lines of prevention than treatment, would involve injection of genes into a disc adjacent to a 
spinal fusion. Here the intent would be to modulate the biological activity within the disc to 
enable the disc to better withstand the abnormal mechanical loads that presumably occur 
following fusion. With gene therapy, there is a possibility to delay or even prevent disc 
degeneration (Figure 1).  
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Figure 1 Potential regeneration ability of gene therapy   
 
 
1.1.4 Therapeutic Potential of Ad/BMP-2 and Ad/BMP 12 
 
 
The introduction of viral vectors carrying growth factor BMP-2 and BMP-12 genes to the 
degenerated intervertebral disc can potentially stimulate matrix synthesis. BMP-2 induces 
formation of cartilage, bone, and the connective tissues associated with the skeleton.28,29  BMP-2 
also has been reported to increase proteoglycan synthesis in rat intervertebral disc cells in-vitro.30   
BMP-12 plays crucial roles in the formation or induction of various tissue and organ during 
development.31, , , , ,32 33 34 35 36  Recently, BMP-12 has been reported to stimulate formation of tendon 
and cartilage-like tissue, suggesting its potential for reparative function in IDD.37,38  Unlike 
BMP-2, BMP-12 does not stimulate bone matrix synthesis.39  BMP-12 may have the potential to 
promote proteoglycan as well as collagen synthesis in the disc.   
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1.1.5 Importance of Nutrition 
 
 
The disc is the largest avascular organ in the body and it is suggested that lack of nutrition may 
be one of the cause for disc degeneration.40  Solute transport into the intervertebral disc depends 
on diffusion and fluid flow.41  The two main routes for supply of nutrition and removal of small 
waste products in the disc are diffusion through blood vessels adjacent to 1) the annulus fibrosus 
and 2) the hyaline cartilage endplates (Figure 2).31,42  Outer annulus can receive nutrients from 
the blood vessels in the soft tissues around the annulus periphery, and 10% of the endplate 
surface area is immediately adjacent to the vascular capillaries. However, the inner annulus and 
the nucleus pulposus rely on the diffusion of their nutrient supply over long and precarious 
path.43  The endplates are impermeable to large molecular weight molecules, and with age, the 
endplates become remodeled and calcified restricting nutrient supply.44  
 
  
 
 
 
 
 
 
Figure 2 Nutrition routes into the intervertebral disc, adapted from Holm, 1990 
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 The mechanical function of the disc depends on the disc matrix produced by disc cells.  
With sufficient nutrition in the disc, cells will continue producing proteoglycans that can draw in 
water to hydrate the disc.  When nutrition in the disc is restricted, cell viability may decrease in 
the nucleus and thus decrease matrix synthesis and water content.  Insufficient nutrition and 
inefficient removal of metabolic waste products can affect disc health and cell viability.30    
 Motion of the disc with long-term exercise can positively affect transport in the disc.  
Fluid expression during compression and the fluid imbibitions due to relaxation can facilitate the 
transport of larger molecules with lower diffusion coefficients.  Small molecules have high rates 
of diffusion and will not be affected as much by fluid flow.  Short-term exercises that produce 
about 5% of expansion and compression of the disc height has not been shown to change the 
movement of small molecules.45,46,47  Prolonged exercise, immobilization due to fusion, 
d smoking are some of the factors that may also influence disc nutrition by 
disturbing the circulation and transport of the nutrients into the disc.48  
Glucose concentration and oxygen tension is low in the center of the nucleus.  Due to low 
oxygen in the nucleus, part of the glucose is metabolized through the anaerobic pathway.  
Lactate is produced in this pathway and it can lower the pH level in the disc.  Lactate 
accumulation in the nucleus is not well understood, however the acidic environment can enhance 
some degradative enzymes which could affect disc health.32,49  
desired effect in treating the IDD.  To achieve gene transfer, it is essential to have viable cells to 
produce the desired growth factors and synthesize matrixes.  Due to the importance of disc 
vibration, an
Without adequate nutrition, cell number can decrease and gene therapy may not have the 
 24
nutrition, further research in growth factor and gene therapy that is mindful of the nutritional 
aspects of the disc is needed.   
 25
  
 
2.0 SPECIFIC AIMS 
 
2.1 Part I:  Growth Factor and Gene Therapy Study in Cell Culture 
 
• Determine the dose-dependent effects of rhBMP-2 and rhBMP-12 on matrix synthesis 
(PG, collagen, non-collagenous protein synthesis) in NP monolayer culture 
• Determine the dose-dependent effects of rhBMP-12 on matrix synthesis in AF monolayer 
culture 
• Determine the effects of adenovirus mediated delivery of BMP-12 cDNA  
on matrix synthesis in AF and NP pellets culture 
 
 
2.2 Part II: Disc Nutrition Study in Organ Culture 
 
• Develop rabbit disc organ culture method 
• Study the effect of FBS concentration on disc metabolism in organ culture 
• Analyze disc wet weight, dry weight, % hydration, DNA, GAG, and lactate content in the 
AF and NP of freshly harvested as well as cultured discs   
• Examine cell morphology and cell viability in organ culture 
• Attempt marker gene transfer (Ad/lacZ and Ad/Luciferase)  
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3.0 BACKGROUND 
 
 
3.1 Disc Structure and Composition 
 
 
The human spine consists of 33 vertebrae: 7 cervical vertebrae, 12 thoracic vertebrae, 5 lumbar 
vertebrae, 5 sacral vertebrae, and 4 coccyxgeal vertebrae.  An intervertebral disc is between each 
of the intervertebral bodies, except for C1-2, second sacral and Coccyxgeal vertebrae.  
Intervertebral discs make up about one fourth of the length of the vertebral column above the 
sacrum.31  The disc has a gelatinous nucleus pulposus (NP) at the center region surrounded by a 
laminated, fibrous annulus fibrosus (AF). The nucleus occupies about 40% of the disc’s cross-
sectional area. 50  The annulus is composed of lamellae with collagen fibers of each layer runs at 
30 degrees angles to each other.   The cartilaginous endplates locate between the bone and the 
disc.12  Figure 3 illustrates the spine and different views of the intervertebral disc.   
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a. Sagittal Section 
b. Cross Section 
Figure 3 Schematic view of the spine and intervertebral disc, adapted from Holm 1990 (a), 
Corrigan 1998 (b,c) 
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A disc is mostly composed of proteoglycans, collagen, and water.  A healthy NP is rich in 
proteoglycans and type II collagen, and has high water content.  The AF contains type I collagen.   
The water content of the NP is 90% at birth, decreases to about 80% at maturity and decreases 
further to 70% or less in old age.41    Water content of the AF remains relatively constant at 70% 
throughout its lifetime.   
Proteoglycans play an important role in the disc because they are they are negatively 
charged and thus highly hydrophilic.  They can draw water into the disc by creating an 
imbalance of ion concentrations between the inside and the outside of the disc.51,    52
Proteoglycans account for 50% of the NP dry weight and 10-20% of the AF dry weight.  The 
structure of the proteoglycan consists of a protein core and carbohydrate that bond to the core 
protein covalently.  The most common carbohydrate, or glycosaminoglycan (GAG) chains, are 
chondroitin sulfate and keratin sulfate in the disc.  Other proteoglycans include versican, decorin, 
biglycan, fibromodulin, and lumican.53  
Another important protein in the disc is collagen.  Collagen provides the structural 
integrity and mechanical strength of the disc.  Collagen accounts for 65-70% of the AF dry 
weight and 15-25% of the NP dry weight.  The AF has 60% of type I and 40% of type II 
collagen.  The outer annulus is almost all type I collagen, and the percentage of type II collagen 
increases toward the center.  The inner annulus-nucleus interface is almost all type II collagen.  
Collagen molecules are linked by cross links formed on hydroxylysine residues along the 
collagen molecule.  The cross-linking protects the collagen framework from mechanical 
disruption and provides strength and stability.54  There are other proteins besides collagen.  
Theses non-collagenous proteins include matrillins, core proteins on which GAGs are attached, 
fibromodulin, and enzymes involved in collagen processing and crosslinking, etc.  These non-
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collagenous proteins play an important role in extracellular matrix organization.  Some of these 
proteins bind to collagen and participate in fibrillogenesis and matrix assembly.  
For human discs, cells take up about 5% of the matrix volume. The cellularity is 4,000 
cells/mm3 for NP, 9,000 cells/mm3 for AF33.  Table 1 shows the disc composition in human and 
rabbit discs.   
 
Table 1  Disc composition in human and rabbit discs 
 
Human Disc Composition 
• Disc Hydration: 3-5 g/g dry wt, 1-2 g/g dry wt outer AF, 2-3 g/g dry wt inner AF 
• GAG Content: 0.15-0.35 g/gdry wt NP, 0.05 g/g dry wt outer AF, 0.1-0.15 g/g dry wt 
inner AF 
• Collagen Content: 0.15-0.25 g/g dry wt NP, 0.5-0.6 g/g dry wt outer AF, 0.15-0.3 g/g dry 
wt inner AF 
• Lactate: 1-2 mmol/g wet wt NP near endplate, 10-15 mmol/g wet wt NP near center  
• pH: 6.8-7.4 Healthy, 6.6-7.5 Degenerated 
• Oxygen Concentration: 4-10 mmHG in central NP 
 
Rabbit Disc Composition 
• Disc Hydration: 77% in NP 
• DNA Content: 10 µg/ NP, 4.1 µg/AF 
• GAG Content: 1987 mmol GAG/disc, 320 mmol of chondroitin sulfate/mg dry wet in 
NP, 240 mmol of chondroitin sulfate/mg dry wt in AF 
• PG Synthesis: 10-27.1x10-6 mmol of incorporated sulfate/hr/g dry wt 
• Lactate: 14.4 mmol/g wet wt in whole disc 
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3.2 Disc Metabolism 
 
 
Metabolism is the totality of the physical and chemical processes occurring in a living organism, 
which may be partitioned into anabolism and catabolism.  Catabolism, or degradation, is the 
breakdown of complex molecules to simple molecules to reuse their components and/or to 
generate energy.  Anabolism, or biosynthesis, is the synthesis of complex molecules from simple 
molecules and it usually requires energy.55  Living cells require energy to make small molecules 
such as amino acids and nucleotides as well as large molecules such as DNA, RNA, and 
proteins.  Energy is also required for basic cellular mechanisms such as transport of ions and 
metabolites.  Energy is stored and transferred through adenosine triphosphate (ATP).  The 
hydrolysis of ATP gives 7.3 kcal/mol.   A disc cell’s carbon and energy source comes from 
glucose.  In the cell, glucose goes through glycolysis and becomes pyruvate.  There are two 
pathways to break down pyruvate: aerobic and anaerobic respiration (Figure 4).56    
 
 
Aerobic 
Pathway 
Anaerobic 
Pathway 
 
Figure 4 Glycolysis and breakdown of pyruvate, adapted from Voet, 2002 
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Oxygen tension can be as low as 1% in the center of the disc.57  Due to the low oxygen 
tension within the disc, 98.5% of the glucose is metabolized through anaerobic pathway 
producing lactate.49  Lactic acid production is dependent on oxygen tension levels. When oxygen 
tension decreases from 10% to 1%, lactic acid production doubled. 57   Lactate accumulation in 
the disc can cause a lower pH and affect the health of disc cells.   
1.5% of the glucose is metabolized through the aerobic path way in the center of the disc.  
When cells use the aerobic pathway of glycolysis, it goes through oxidative phosphorylation.  
Study by Ishihara and Urban have suggested that an important fraction of the energy production 
of the disc comes from oxidative phosphorylation.57  In the outer area of the disc, oxygen tension 
is higher and energy production from oxidative phosphorylation increases.  In the aerobic 
pathway, complete oxidation of a mole of glucose gives rise to 38-mol adenosine triphosphate 
(ATP), whereas anaerobic glycolysis produces only 2-mol ATP.  The equations below show that 
the anaerobic pathway is 19 times less efficient than the aerobic pathway.46    
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 3.3 Gene Transfer 
 
 
Gene therapy is the introduction of a gene to specific tissues and cells to allow gene expression 
of the inserted gene product.58  Successful gene therapy for IDD should direct disc cells to 
produce more proteoglycan and collagen.  Ultimately, one of the goals of the gene therapy is to 
give the disc more water content in the nucleus and to regain or maintain its ability to withstand 
mechanical loads.  With this in mind, the gene of interest is chosen based on its potential ability 
to stimulate matrix synthesis.  
There are many ways one can deliver the gene of interest into the cells, and some 
methods are more effective than others.  Besides the method of delivery, sufficient amounts and 
duration of gene expression also determine if successful gene transfer can be achieved.  Two 
main approaches for gene delivery are viral and non-viral vectors.  Viral systems have been 
shown to be more successful than the non-viral systems currently available.59  Viral vectors 
include retrovirus, adenovirus, adeno-associated virus.  Some of the non-viral transfection agents 
are liposomes, PLL, and PEI.60,61  In this study we have chosen adenovirus as our gene delivery 
vehicle because of its effectiveness in gene delivery.62  We have shown upregulated matrix 
synthesis in disc cells treated with Ad/TGF-β1 in previous studies.27  In this study we have 
chosen Ad/BMP-12 gene to investigate its potential to stimulate matrix synthesis in disc cells.  
There is a risk of immune responses in viral gene therapy. However, our group had previously 
shown that the disc provides an immune-privileged environment for adenoviral gene therapy 
because of its avascular structure.        
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 3.4 Culture Systems in Disc Metabolism Study 
 
Culture systems to study the disc metabolism include cell, tissue, and organ culture.        Most 
studies are done in cells or tissues from small animals because large animal studies are expensive 
and human material is difficult to obtain.  In human material, the cellular activity is low from 
discs taken postmortem.63   
 In tissue culture, the key issue is maintenance of PG in the tissue.  Thompson et al 
cultured canine disc tissue in serumless medium to study the effect of growth factors on matrix 
synthesis.26   In their culture, they observed low PG content for 3 to 4 days and the culture was 
maintained for up to 8 days.  Bayliss et al cultured disc tissue in a dialysis bag with polyethylene 
glycol (PEG) and were able to maintain PG in the disc for 6 hours.64  However, the daily 
replacement of medium in the dialysis bag increased the contamination risk and exposure to 
PEG, which is toxic to the tissue.     
To minimize loss of PG in the NP, Chiba et al developed an organ culture method to study 
the metabolism of the rabbit disc.65  They have cultured discs up to 1 month and observed a 
decrease in tissue dry weight, DNA, as well as PG.  Takegami, Masuda, and An are continuing to 
develop the organ culture method to study disc metabolism using intact intervertebral discs.  
Their disc culture contains disc and endplates.  The authors did not indicate in the abstract that 
intervertebral bodies were kept with the disc in the culture.  Discs were injected with OP-1 and 
maintained in the culture for 2 weeks.66     
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3.5 Summary of Literature 
 
 
• Part I: Growth Factor and Gene Therapy Study in Cell Culture 
BMP-2 was shown to increase proteoglycan synthesis in rat intervertebral discs.30   Studies have 
shown that BMP-12 stimulates formation of tendon-like tissue in-vivo, suggesting its potential 
for reparative function in AF cells.37,38  Although there have been some reports showing the 
potential of gene delivery in NP cells, no reports were found showing virus mediated gene 
therapy to increase matrix synthesis in human AF cells from degenerated discs.  
 
• Part II: Disc Nutrition Study in Organ Culture 
Research on the nutrition of the intervertebral disc began in the late 1920’s. 40   However disc 
nutrition is still poorly understood because it is difficult to maintain the integrity of the tissue in-
vitro.  Studies had been done in NP culture, but PG comes out of the tissue very quickly.25  In 
order to maintain PG in the disc, whole organ culture was developed.  There are currently 
ongoing nutrition studies on the effect of OP-1 stimulation using whole organ culture by 
Takegami et al.66  No study was found on the effect of gene therapy in a disc organ culture.   
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 3.6 Overview of Proposed Study 
 
All of the experiment protocols were approved by the Institutional Animal Care and Use 
Committee and Institutional Biosafety Committee at the University of Pittsburgh.   
 
• Part I: Growth Factor and Gene Therapy Study in Cell Culture 
The effect of rhBMP-2 and rhBMP-12 on matrix synthesis will be examined in the NP 
monolayer culture. Although the half life of growth factors is short, the study will be necessary 
to screen their effect on disc cells.  Proteoglycan, collagen, and non-collagenous protein 
synthesis will be measured.  Different doses of the growth factors will be used to compare the 
effect of rhBMP-2 and rhBMP-12.  After screening the effect of these growth factors, we will 
use adenovirus for gene transfer of Ad/BMP-12 to determine its efficacy.  Ad/BMP-12 will be 
administered on AF and NP cells in a pellet culture to study its effect on matrix synthesis.  The 
differences between AF and NP cells’ response to Ad/BMP-12 will be examined.  Figure 5 
shows the project design of Part I of the study of the effect of growth factor and gene therapy on 
matrix synthesis of human disc cells.   
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NP Cells in Monolayer 
(10 Patients) 
NP and AF Pellets 
(8 Patients) 
Non-collagenous Protein 
Syntehsis 
Proteoglycan 
Synthesis 
Collagen 
Synthesis 
rh BMP-2 (0, 25, 50, 100, 200, 300 ng/ml) 
rh BMP-12 (0, 25, 50, 100 ng/ml) 
Ad/BMP-12 (0, 50, 100, 150 MOI) 
Gene Therapy 
Measure Matrix Synthesis 
Growth Factor 
 
Figure 5  Project design of Part I: Growth Factor and Gene Therapy Study in Cell Culture 
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• Part II: Disc Nutrition Study in Organ Culture 
A method for organ culture of rabbit intervertebral disc will be developed in Part II of the study.  
Effects of different concentrations of nutrient on the metabolism of the disc in the culture will be 
determined.  Whole rabbit discs will be incubated in medium containing different percentage of 
fetal bovine serum (FBS).  Disc hydration, GAG, DNA content, lactic acid will be measured.  
Histology of cultured and non-cultured discs will be used to show cell morphology.  Cell 
viability of cultured discs will be investigated.  BMP-2 content in the tissue of non-cultured discs 
will also be measured to establish baseline composition data.  Then Ad/lacZ and Ad/Luciferase 
will be injected into the discs to attempt gene transfer.  Figure 6 shows the project design of Part 
II of the study on disc nutrition in organ culture.  
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Fresh Discs 
Cultured Discs 
 
Disc Hydration 
 
Lactate Content 
 
GAG Content 
 
DNA Content 
 
BMP-2 Content 
(ELISA) 
(1 rabbit) 
Cell Morphology 
(Histology) 
(1 rabbit) 
Cell Viability 
Cell Morphology 
Histology 
(1 rabbit) 
Effect of % FBS on 
Disc Metabolism 
(0, 5, 10, 15% FBS) 
(4 rabbits) 
Marker Gene Transfer 
(6x106 PFU) Ad/Luciferase 
(2 rabbits) 
Ad/lacZ 
(3 Rabbits) 
Baseline Composition 
(2 rabbits) 
 
 
Figure 6 Project design of Part II: Disc Nutrition Study in Organ Culture  
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4.0 METHODS 
 
 
4.1 Part I: Growth Factor and Gene Therapy Study in Cell Culture 
 
4.1.1 Disc Cell Isolation 
 
 
AF and NP tissues from degenerated discs were harvested from 18 patients during surgical disc 
procedures performed for herniated disc and spinal stenosis. The specimens were rinsed with 
saline three times in a Petri dish.  Tissues were minced in a sterile conical glass tube into small 
fragments of approximately 2mm3 volumes each in a sterile conical glass tube.  Tissues were 
digested in Ham’s F-12 medium (F-12, GIBCO-BRL, Grand Island, NY) with 1% 
penicillin/streptomycin (P/S), 5% FBS (fetal bovine serum, GIBCO-BRL, Grand Island, NY), 
and 0.2% pronase (Calbiochem, La Jolla, CA) for 90 minutes. Cells were washed with 20ml of 
saline 3 times and then incubated in 0.01% collagenase type II (Sigma, St. Louis, MO) overnight 
at 37°C dry incubator under gentle agitation in a filter glass.  Cells were isolated through a sterile 
nylon mesh (75µm pore size) and centrifuged at 2000 RPM for 5 min. Cells were resuspended in 
Ham’s F-12 with 10% FBS and 1% P/S seeded in monolayer and cultured with F-12 medium 
(containing 1% PS, 50µg/ml L-ascorbic acid) in a 5% CO2 incubator until confluency.67  
Depending on amount of tissue received, confluency was typically attained within 2 to 3 weeks.  
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4.1.2 rhBMP-2 and rhBMP-12 Stimulation in Monolayer Cell Culture 
 
 
NP cells harvested from 10 patients (cervical and lumbar discs) were processed as described in 
Section 4.1 and incubated in serumless media with 1% ITS+ (premix) for 2 days with BMP-2 
(25, 50, 100, 200, 300 ng/ml) or BMP-12 (25,50,100 ng).  Cells were then incubated with 35S or 
3H-proline to measure matrix synthesis as described in Sections 4.4 and 4.5, respectively. 
Experiments were performed in triplicate and the data was normalized by cell number.  Cells 
were trypsinized and centrifuged at 2,000 rpm for 5 min. Then cells were resuspended and cell 
solution was pipetted onto each side of the hemocytometer.  A manual counter was used to count 
the cells in the grids under the microscope.  Only live cells were counted.         
 
 
4.1.3 Ad/BMP-12 Transduction in 3D Pellet Culture 
 
 
NP and AF cells were isolated from 8 patients (cervical and lumbar discs) as described in Section 
4.1. Monolayer cells were incubated with Adeno/BMP-12 (0,50,100,150 MOI) for 6 hrs.  
Knowing the number of cells and multiplicity of infection (MOI), the amount of virus needed in 
plaque forming unit (PFU) was calculated using this equations below: 
Cell
PFUMOI =  
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 After Ad/BMP-12 transduction, monolayer cells were trypsinized and made into pellets by 
centrifuging at 2000 RPM for 5 minutes. A hemocytometer was used to count the cells as 
described in Section 4.1.2 and each pellet was made with approximately 150,000 cells. Therefore 
0, 7.5x105, 1.5x106, 2.25x107  PFU per pellet was used for 0, 50, 100, 150 MOI respectively.  
Pellets were incubated in serumless media with 1% ITS+ (premix) for 6 days.  Experiments were 
performed in triplicate and data was normalized by DNA content as described in Section 
4.3.2.1.3. 
 Viral vectors were provided by the Paul D. Robbins, PhD of Department of Molecular 
Genetics and Biochemistry.  In the adenoviral vector construction, each recombinant adenoviral 
vector originated from replication-deficient Type 5 adenovirus lacking E1 and E3 loci. 
Complementary DNAs were cloned into the E1 region, and expression was driven by a human 
cytomegalovirus (CMV) promoter. Hight-titer suspensions of recombinant adenovirus were 
prepared by amplification in confluent monolayers of transformed human embryonic kidney 293 
cells.  Titers were estimated from the optical density at 260 nm and standard plaque assay.27  
 
 
4.1.4 35S-Sulfate Incorporation 
 
 
Cells or pellets were incubated in Newman Tytell seamless medium containing 35S-sulfate (10 
µCi/ml) for 7 hours. The medium was replaced by Guanidine Hydrochloride (GuHCl) and 
samples were digested by shaking in the cold room (-20oC) for 48 hours. Then 200µl of medium 
and extract from each sample were applied to chromatography on Sephadex G-25 in PD-10 
columns (Pharmacia Biotech, Uppsala. Sweden) equilibrated and eluted with 4M GuHCl 
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containing 0.05M Tris and 0.05 M Na2SO4. The 1 mL fractions were collected in scintillation 
vials mixed with 7 mL of scintillation fluid (Ultima Gold, Packard Mariden, CT) and counted by 
a liquid scintillation counter (Packard=1990 TR, Mariden, CT).68   
 
 
4.1.5 3H-Proline Incorporation 
 
 
Cells or pellets were incubated with serumless media containing 50 µg/ml ascorbic acid, 50 
µg/ml β-amino-propionitrile, and 10 µCi of 3H-proline/ml, then incubated at 37°C for 24 hours.    
After incubation, the medium was collected and the samples were treated with homogenizing 
buffer (0.5ml/well) and subjected to three freeze/thaw cycles at –80˚ C for 2 hrs to homogenize 
the cell extracts 2 times.  The samples were then stirred with magnetic micro stirring bars (Cat. 
No. 14-511-67, Fisher Scientific, Fair Lawn, New Jersey) at 4˚ C for overnight, and then the 
medium and cell layer were combined and relative collagen synthesis was determined by 3H-
proline incorporation using a modified collagenase digestion method69. Briefly, a carrier protein 
(2 mg/ml of pepsin-solubilized bovine type I collagen) was added and the proteins were 
precipitated by addition of 10% trichloroacetic acid (TCA). The TCA-precipitated proteins were 
recovered by centrifugation at 13,000 rpm for 10 min at 4°C. The recovered protein pellets were 
resuspended in 1ml of 1mM proline solution, and washed with 5% TCA to remove the unbound 
isotope. This step was repeated three times. After repeated washing with TCA the pellets were 
resuspended in the collagenase buffer (5 mM CaCl2 and 3 mM N-ethylmaleimide) and purified 
bacterial collagenase ABC form III  (Advanced Biofactures, Lynbrook, NY) (20 U/ml). The pH 
was adjusted to 7, and pellets were incubated at 37°C for 2h. After incubation, the samples were 
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cooled down on ice, then TCA was added and the mixture was centrifuged for 10 min at 13,000 
rpm. The collagenase-digestive proteins were separated from non-digested proteins by addition 
of 5% TCA followed by centrifugation at 13,000 rpm for 10 min. For radioactive scintillation 
counting for collagen synthesis, 1 ml of the supernatant was taken out and mixed with 6 ml of 
scintillation fluid. The pellets were redissolved in 0.2 M NaOH and aliquots of the pellets were 
subjected to radioactive counting to determine the level of noncollagenous protein synthesis. 
Data were normalized by Pico Green dsDNA quantitation. (Molecular Probes, Eugene, OR) 
 
 
4.2 Part II: Disc Nutrition Study in Organ Culture 
 
 
4.2.1 Organ Culture 
 
 
Six skeletally mature New Zealand White rabbits (4-5 kg) were used in this study.  After 
sacrifice and harvest of the spines, muscles were removed as quickly as possible. Using a bone 
cutter, the discs were cut in the center of vertebral body (Figure 7). Discs were kept moist with 
saline and bone marrow was flushed out using a 21G needle with saline containing 1% P/S.  
Discs were then washed with 10ml of saline with 1% P/S for 6 times.  Five discs were harvested 
from each rabbit (L1-2, L2-3, L3-4, L4-5).  Discs from 4 rabbits (1,2,3,4) were cultured for 2 
weeks in media containing different % FBS.  Discs from rabbit 1,2,3,4 were cultured in 
serumless media, 5%, 10%, or 15% FBS F12/DMEM respectively.  Discs from 2 rabbits were 
not cultured to serve as fresh controls.  Originally, we did not culture the disc with bone.  We 
observed cracking of the endplate in many discs and NP came out of the disc during the culture.  
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When we left the vertebral bodies on the disc, we saw less swelling of the disc and it prevents 
cracking of the endplate.    
 
Figure 7  a) Bone-disc-bone sample  b) Whole discs in  culture 
a. 
b. 
Intervertebral discs were separated 
by bone cutter by cutting at the 
middle point of the intervertebral 
bodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 45
 
 
4.2.2 Gene Transfer 
 
 
Twenty-five discs from 5 rabbits were harvested.  Discs were first cultured in serumless media 
for 2 days after harvest.  6x106 plaque forming units (PFU) of Ad/lacZ in saline, Ad/Luciferase 
in saline, or saline only was injected into the disc with a 30G needle (Figure 8).  Three discs 
from one rabbit were injected with Ad/Luciferase.  Two discs from the same rabbit were injected 
with saline as controls.  Twenty discs from 4 rabbits were injected with Ad/lac-Z or saline 
control.  Among the 20 discs, 4 culturing conditions (0%, 5%, 10%, 15% FBS) were used with 5 
discs for each condition.  The amount of virus stock solution needed (Z) per disc was calculated 
by the following equations: 
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X is the concentration of the virus stock solution in the unit of particles per ml and it is 
converted to Y in units of PFU.  Z amount of virus stock solution was mixed with saline to make 
a total of 10µl of viral solution to inject into each disc.  X varied with the batch of virus, 
therefore Z was different for different viruses. For example, X for the specific batch of Ad/lacZ 
that we used was 4.38x1012, Z was calculated to be 0.137 µl using the equations above.  We 
multiplied Z by the number of discs that were going to be injected.  Zx6 discs equaled 0.0.822 µl. 
To ensure accuracy, a larger amount of the virus stock solution was taken because we cannot 
pipette an amount smaller than 1 µl.  It was best to use more than 5 µl, therefore we chose to take 
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5.48 of virus stock solution and mixed it with 394.52 µl of saline.  When we take 10 µl of this 
virus solution, there would be 0.137 µl of virus stock and 9.863 µl of saline.  After injection, the 
needle was left inside the disc for 20 seconds before slowly being withdrawn to minimize the 
amount of solution  leaking out of the disc.  The injection was carefully done in a sterile hood to 
minimize contamination.  The discs were incubated in the media for one week before analyzing 
the effect of gene transfer.  
 
       
      Figure 8 Injection of Ad/lacZ or Ad/Luciferase 
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4.2.3 Outcome Measures 
 
 
4.2.3.1 Cells 
 
 
4.2.3.1.1  Cell Morphology 
 
Histology was used to observe cell morphology in fresh discs and cultured discs. Discs from one 
rabbit were non-cultured.  Discs from another rabbit were cultured in serumless media for 2 
days.  There were a total of 9 discs, 5 fresh discs and 4 culutred discs.  Discs were fixed in 10% 
buffered formalin for 3 days, processed using a tissue processor (Tissue-Tek VIP, Sakura Finetek 
USA, Torrance, CA), and dehydrated overnight.  It was processed and dehydrated using 70% 
ETOH 45 min, 80% ETOH 45 min, 95% ETOH 45 min 2 times, 100% ETOH 2 times, xylene 
45min 2 times, and then paraffin 4 hrs.  The endplates were removed by a scalpel (#10 blade).  
Tissue was embedded in paraffin and 10µm thick cross sections were prepared using a 
microtome (Cut 4055, Olympus, Melville, NY) and stained with (H&E) Hematoxylin and Eosin. 
Hematoxylin stains for the nucleus and Eosin stains for plasma.  The stain theory is based on the 
attractions of oppositely charged tissue and dye molecules.  Hematoxylin binds to DNA, RNA, 
and acidic proteins in a cell because it is binds to negatively charged molecules.70       
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4.2.3.1.2  Cell Fate 
 
Cell viability was detected with CMFDA (Molecular Probes, Eugene, OR) and propidium iodide 
(Calbiochem, San Diego, CA).  Cell tracker CMFDA can diffuse into the live cell, where 
cytosolic esterases cleave the acetate groups and release a green fluorescent product.  Propidium 
iodide can diffuse through the membrane of nonviable cells and bind to double-stranded nucleic 
acid and produce a red fluorescent product.  Whole NP was taken out by a forceps and kept 
moist at all times.  For AF and Transition Zone (TZ), samples from four different regions of the 
discs were harvested with a scalpel.(Figure 9)  1mm thick sections of AF, TZ, or the whole NP 
was incubated in 250µl of CMFDA and 250µl of prodidium iodide solution for 30min at room 
temperature. Samples were washed 2 times with PBS and fixed in 2% paraformaldehyde for 1 
hour at room temperature. After washing for 2 times with PBS, samples were stored in PBS at 
4oC before imaging with 2-photon laser scanning microscope (IX 70, Olympus, Melville, NY) or 
fluorescent microscope (Eclipse E 800, Nikon, Melville, NY).   
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2 AF 
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4 TZ
1 TZ 
1 AF 
 
Figure 9 AF and TZ were obtained 
staining 
 
 
4.2.3.1.3  DNA Content 
 
 
Tissue of AF and NP were harvested
volume. Tissue was dried using Sav
hours.  Then tissue was digested in p
cysteine HCl, papain 2.5 mg/ml) ove
Green dsDNA Quantitation Reagent
curve for dsDNA was generated from
buffer and 100 µl of the diluted sam
 3 TZ 
3 AF 
from four regions of the disc, whole NP was taken for 
 and AF was cut in smaller pieces of approximately 2mm3 in 
ant Speedvac (Savant Instruments, Farmingdale, NY) for 2 
apain buffer (50mM phosphate buffer, 5 mM EDTA, 5mM 
rnight at 65oC. Then DNA content was analyzed using Pico 
 and Kits (Molecular Probes, Eugene, OR).  A standard 
 10ng/ml to 1000 ng/ml.  Samples were diluted in TE 
ples were pippetted into a 96 well plate.  Then 100µl of Pico 
50
Green solution was added to the samples and standards and samples were run using the 
fluorometer with 485 nm excitation filter and 528 nm emission filter.     
 
 
4.2.3.2 Biologic Activity of Cells 
 
 
4.2.3.2.1  Growth Factor Production 
 
 
Five discs from one rabbit was used to determine the BMP-2 level in a non-cultured disc.  
ELISA (R&D systems Quantikine BMP-2 Immunoassay, catalog Number DBP200) was done 
for both media and tissue. BMP-2 in the tissue was extracted by 2M Guanidine-HCL with 
protease inhibitors (0.05 M Tris, 5mM EDTA, 5mM Benzamidine, 5mM N-ethylmaleimide, 
2mM PMSF) overnight, stirred in the cold room. Samples were then centrifuged and the 
supernatant was diluted so that the final concentration was less than 0.06 M prior to the assay. 
This assay used the quantitative sandwich enzyme immunoassay technique.71  A monoclonal 
antibody specific for BMP-2 was pre-coated onto a microplate. Standards and samples were 
pipetted into the wells and any BMP-2 present was bound by the immobilized antibody. After 
washing away any unbounded substances, an enzyme-linked monoclonal antibody specific for 
BMP-2 was added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution was added to the wells and color developed in proportion to the 
amount of BMP-2 bound in the initial step. The color development was stopped and the intensity 
of the color was measured. 
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4.2.3.2.2  lacZ Marker Gene Expression 
 
 
To evaluate lacZ transgene expression qualitively, beta-galactosidase expression was analyzed 
using the X-Gal histochemical staining technique.72  A total of 15 Discs from 3 rabbits were 
cultured in serumless medium for 2 days, injected with Ad/LacZ or saline control, and cultured 
for 1 more week. The discs were frozen in liquid nitrogen and 8um thick transverse serial 
cryostat sections were obtained. The sections were rinsed in PBS and fixed in 0.5% 
glutaraldehyde at 4oC for 10min.  Then sections were rinsed twice in PBS with 1mM MgCl2. 
The sections were then incubated in X-gal substrate overnight at 37oC. X-gal substrate contains 
20X KC (0.82 g K3Fe, 1.05 g K4Fe, 25ml PBS), 1M MgCl2, 40mg/ml X-gal in DMSO, and 
PBS. The blue X-Gal reaction product was used to indicate expression of the lacZ product beta-
galactosidase.   
 
 
4.2.3.2.3  Luciferase Marker Gene Expression 
 
 
Luciferase transgene expression was quantified using a standard luciferase assay kit (Promega). 
Ten discs from 2 rabbits were cultured in serumless medium for 2 days, injected with 6x106 PFU 
Ad/luciferase or saline control, and then cultured for 1 week in 10% FBS. The NP was harvested 
and homogenized with 200µl of 1X cell culture lysis buffer by vortexing for 15 seconds. The 
samples were centrifuged at 13,000 RPM for 1 minute at 4oC, and the supernatant was 
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transferred to a new tube. Luciferase assay reagent was mixed with cell extract and light 
production was measured with a luminometer and expressed in relative light units (RLU). 
 
 
4.2.3.3 Extracellular Matrix (ECM) Composition 
 
 
4.2.3.3.1  GAG Content 
 
 
This assay measured the GAG content in the medium as well as the digested tissue.  Tissue was 
digested by the method described in Section 4.8.2.  This assay determines the change in 
absorption spectrum of the dye 1,9 dimethylmethylene blue (DMB) when it is complexed with 
sulfated GAG.73  It gives a quantitative determination of total GAG content in a sample of 
proteoglycans. The standard curve was given by condroitin-6-sulfate (Sigma, Cat #C-4384).  
40µl of samples and standards (0 to 60 µg/ml) were pipetted into a 96 well plate. Then 250µl of 
DMB reagent was added into each well. The plate was read by the plate reader within 5 minutes 
at 540 and 595 nm.  
 
 
4.2.3.3.2  Water Content 
 
 
NP and AF of the discs were harvested with a scalpel (#10 blade) and immediately weighed on 
pre-weighed vials using a digital balance (AE 200, Mettler Instument Corp., Hightstown, NJ) to 
obtain wet weight.   Then tissue was dried using Savant Speedvac (Savant Instruments, 
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Farmingdale, NY) for 2 hours and the dry weight was measured.  Percent hydration was then 
calculated by the following equation:  
Hydrationx
WetWeight
DryWeightWetWeight %%100 =−  
 
 
4.2.3.3.3  Lactic Acid Content 
 
 
The UV-method was used to determine lactic acid content in the media and digested tissue. (Cat. 
No. 0139084, R-Biopharm, Marshall, MI)  Tissue was digested by the method described in 
Section 4.8.2 DNA content.  0.015 ml of digested sample solution, 0.15 ml of solution 1, 0.03 ml 
of solution2, 3 µl of solution 3, and 0.135 ml of distilled water were mixed by vortexing.  Mixed 
solution was let stand for 5 min, and then absorbances of the samples A1 were read using the 
plate reader at 365nm.  0.003 ml of solution 4 was then added to the mixture.  After 30 min, 
absorbances A2 absorbances were read at 365nm.  Delta A was obtained by subtracting A1 from 
A2.  Concentration of NADH (c) was calculated by the following eqation: 
12 AADeltaA −=  
ExDeltaA
c 018.2=  
The measured amount of NADH is the same amount of the L-lactic acid in the sample.  E 
equals 3.4 at 365nm.  L-Lactic acid (L-lactate) is oxidized to pyruvate by nicotinamide-adenine 
dinucleotide (NAD) in the presence of L-lactate dehydrogenase (L-LDH).  By trapping pyruvate 
in a subsequent reaction catalyzed by the enzyme glutamate-pyruvate transaminase (GPT) in the 
presence of L-glutamate, the equilibrium can be displaced in favor of pyruvate and NADH. 
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4.3 Statistical Analysis 
 
The data from Part I: Growth Factor and Gene Therapy Study in Cell Culture were normalized to 
cell count or DNA content.  Mean, standard deviation, and p value of student t-test was 
calculated.  We hypothesized that rhBMP-2, rhBMP-12, and Ad/BMP-12 will increase matrix 
synthesis of disc cells.  For Part II: Disc Nutrition Study in Organ Culture 
, disc nutrition study in organ culture, one way analysis of covariance (ANCOVA) in SAS (Cary, 
NC) was utilized.  Due to small sample size, assumption of no inter-rabbit effect was made.  
However, intra-rabbit effects of different disc levels and unbalanced data due to missing level 
were considered.   We hypothesized that with increasing %FBS in the media, GAG, DNA, and 
lactate will increase.  The list below shows the outcome measures and data normalization:   
 
Part I: Growth Factor and Gene Therapy Study in Cell Culture 
1.   In the growth factor study, mean and standard deviation of proteoglycan, collagen, and 
non-collagenous protein synthesis were calculated.  Data were normalized to cell count.  
P value was set at less than 0.05 to test the significance of the data.    
2.   In the Ad/BMP-12 study, mean and standard deviation of proteoglycan, collagen, non-
collagenous protein synthesis were calculated.  Data were normalized to DNA content.  P 
value was set at less than 0.05 to test the significance of the data.    
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Part II: Disc Nutrition Study in Organ Culture 
1. ANCOVA was used to determine the significance of the data for GAG, DNA and lactate 
content.  P value was set at less than 0.05. 
2. Mean and standard deviation of disc wet and dry weight, % hydration, GAG, DNA, and 
lactate content were calculated.  GAG, DNA and lactate content were normalized to the 
dry weight of the tissue.  
3. The correlation between GAG, DNA, and lactate was determined by Pearson correlation 
coefficients.   
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5.0 RESULTS 
 
 
5.1 Part I: Growth Factor and Gene Therapy Study in Cell Culture 
  
5.1.1 Effect of rhBMP-2 and rhMBP-12 on NP monolayer 
 
In this dose dependent study, we investigated the effect of different doses of rhBMP-2 and 
rhBMP-12 on matrix synthesis of NP cells.  RhBMP-2 significantly upregulated matrix synthesis 
for all doeses (25-300 ng/ml).  We observed a dose-dependent response for proteoglycan, 
collagen and non-collagenous protein synthesis.  Among the range of doses that we studied, 
maximal matrix synthesis by NP cells was observed at concentrations of 200 and 300 ng/ml of 
BMP-2.   The matrix synthesis from 200 ng/ml and 300 ng/ml rhBMP-2 groups were not 
significantly different (p>0.05).  The mean and standard deviation of proteoglycan, collagen, and 
non-collagenous protein synthesis were 386±178%, 310±201%, and 245±113% of control 
respectively (p<0.01) in NP monolayer incubated with 300 ng/ml of rhBMP-2.   
  RhBMP-12 also upregulating matrix synthesis of NP cells.  We investigated a shorter 
range of doses of rhBMP-12 (25-100ng/ml) than that of rhMBP-2 (25-300 ng/ml) because we did 
not observe higher matrix synthesis at higher does in a preliminary study.  We did not see a dose-
dependent response for matrix synthesis.  There is a significant increase in proteoglycan, 
collagen, and non-collagenous protein synthesis.  However, matrix synthesis from 25, 50, 100 
ng/ml groups were not significantly different (p>0.05).  The mean and standard deviation of 
 57
proteoglycan, collagen, and non-collagenous protein synthesis were 158±49%, 138±42%, and 
147±32% of control respectively (p<0.01) in NP monolayer incubated with 100 ng/ml of 
rhMBP-12. 
 In the range of doses that we have tested, rhBMP-2 showed a more substantial effect on 
upregulating matrix synthesis than rhBMP-12 (Figures 10-12).  Raw data is shown in Appendix 
A.   
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Figure 10  PG synthesis in NP treated with rhBMP-2 and rhBMP-12 
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* p<0.01 
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Figure 11 Collagen synthesis in NP treated with rhBMP-2 and rhBMP-12 
Non-collagenous Protein Synthesis in Nucleus 
Pulposus Cells Treated with rhBMP-2 and 
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Figure 12  Non-collagenous protein synthesis in NP treated with rhBMP-2 and rh-BMP12 
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5.1.2 Effect of rhBMP-12 on AF monolayer 
 
In annulus fibrosus, rhBMP-12 at 25 and 50 ng/ml demonstrated significant upregulation in only 
non-collagenous protein synthesis as shown in Figure 15 (p<0.01).  For AF cells treated with 50 
ng/ml of rhBMP-12, mean and standard deviation of non-collagenous protein synthesis was 
127±30% of control. No significant increase of PG or collagen synthesis was observed (Figure 
13,14).  In a preliminary study, we have also treated AF cells with  rhBMP-2 (25, 50, 100 
ng/ml).  Collagen synthesis was significantly increased at rhBMP-2 at 100 ng/ml rhBMP-2 with 
mean and standard deviation of 121±36% of control.    Non-collagenous protein synthesis was 
significantly increased at rhBMP-2 at 25 and 100 ng/ml.  For AF cells treated with 100ng/ml of 
rhBMP-2, the mean and standard deviation of non-collagenous protein synthesis was 151±56% 
of control.  We observed no significant increase of PG synthesis.  Preliminary results of rhBMP-
2 on AF culture monolayer are shown in the Appendix B.   
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Figure 13  PG synthesis in AF treated with rhBMP12 
 
 
Collagen Synthesis in Anulus Fibrosus Cells 
Treated with rhBMP-12
0
50
100
150
200
0 (control) 25 50 100
Dose (ng/ml)
P
er
ce
nt
 o
f C
on
tro
l
 
Figure 14  Collagen synthesis in AF treated with rhBMP-12 
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Non-collagenous Protein Synthesis in Anulus 
Fibrosus Cells tReated with rhBMP-12
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Figure 15  Non-collagen protein synthesis in AF treated with rhBMP-12 
 
 
5.1.3 Effect of Ad/BMP-12 on AF and NP pellets 
 
Newly synthesized PG, collagen, and non-collagenous protein in AF and NP pellets treated with 
Ad/BMP-12 were significantly increased when compared to controls before normalization by 
DNA content for all doses(p<0.01).  In the range of doses we investigated (50-150 MOI), we 
observed highest PG synthesis in AF pellets at 50 MOI.  PG synthesis at 50 MOI is significantly 
higher than 100 and 150 MOI.  For collagen and non-collagenous protein synthesis in AF pellets, 
there were no significant differences between different doses.  In AF pellets treated with 50 MOI 
of Ad/BMP-12, the mean and standard deviation of PG, collagen and non-collagenous synthesis 
were 336±37%, 269±89%, and 222±9% of control respectively before normalization by DNA 
content.  
 *  * 
* p<0.01 
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For NP pellets treated with Ad/BMP-12, PG, collagen, and non-collagenous protein 
synthesis were not significant between different doses.  In NP pellets treated with 50 MOI of 
Ad/BMP-12, the mean and standard deviation of PG, collagen and non-collagenous synthesis 
were 388±31%, 371±46%, and 282±36% of control respectively before normalization by DNA 
content.   
For both AF and NP pellets treated with Ad/BMP-12, total DNA content significantly 
increased (p<0.01).  Total DNA content of AF pellets treated with Ad/BMP-12 were not 
significantly different between different doses.  For AF pellets treated with 100 MOI of 
Ad/BMP-12, the mean and standard deviation of DNA content was 208±16% of control.  Total 
DNA content of NP pellets treated with Ad/BMP-12 were not significantly different between 
different doses.  For NP pellets treated with 100 MOI of Ad/BMP-12, the mean and standard 
deviation of DNA content was 216±50% of control.  After DNA normalization, PG, collagen, 
and non-collagenous protein synthesis in AF and NP pellets treated with Ad/BMP-12 
(50,100,150 MOI) were significantly increased when compared to controls except for non-
collagenous protein synthesis in AF pellets.    
Results of AF pellets before and after DNA normalization are shown in Figures 16-21.  
Results of NP pellets before and after normalization are shown in Figure 22-26.  Raw data for 
NP and AF pellets are included in the Appendix C and D respectively. 
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igure 16  PG synthesis in AF treated with Ad/BMP-12 (before DNA normalization) 
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Figure 17  PG synthesis in AF treated with Ad/BMP-12 (after DNA normalization) 
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Figure 18  Collagen synthesis in AF (before DNA normalization) 
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Figure 19  Collagen synthesis in AF (after DNA normalization) 
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Figure 20  Non-collagenous protein synthesis in AF (before DNA normalization) 
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Figure 21  Non-collagenous protein synthesis in AF (after DNA normalization) 
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Figure 22  PG synthesis in NP treated with Ad/BMP-12 (before DNA normalization) 
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Figure 23  PG synthesis in NP treated with Ad/BMP-12 (after DNA normalization) 
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Figure 24 Collagen synthesis in NP treated with Ad/BMP-12 (before DNA normalization) 
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Figure 25 Collagen synthesis in NP treated with Ad/BMP-12 (after DNA normalization) 
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Figure 26  Non-collagenous protein synthesis in NP treated with Ad/BMP-12 (before DNA 
normalization) 
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Figure 27  Non-collagenous protein synthesis in NP treated with Ad/BMP-12 (after DNA 
normalization) 
Mean and standard deviation of matrix synthesis of AF and NP pellets treated with 50 
MOI of Ad/BMP-12 before and after normalization by DNA content is described in Table 2.  
Matrix synthesis of AF and NP pellets treated with 50 MOI of Ad/BMP-12 were significantly 
higher than control except for non-collagenous protein synthesis in AF pellets after DNA 
normalization.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* p<0.01 
  * * 
    * 
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Table 2  Matrix synthesis of AF and NP pellets treated with Ad/BMP-12 before and after DNA 
normalization (shown in percent of control) 
 
 
 
Matrix Synthesis AF 
(before 
normalization) 
AF 
(after 
normalization) 
NP 
(before 
normalization) 
NP 
 (after 
normalization) 
Collagen 269±89% 129±43% 371±46% 172±21% 
Non-collagenous 
Protein 
222±9% 107±5% 282±36% 131±17% 
Proteoglycan 336±37% 161±19% 388±31% 180±14% 
 
 
 
5.2 Part II: Disc Nutrition Study in Organ Culture  
 
 
5.2.1 General Observations 
 
 
The AF had layered lamellas and AF cells had flat cell shapes.  AF matrix was organized and 
fibers of different layers were oriented at different angles giving the tissue a layered appearance.  
Cells near the periphery of the disc were very flattened and difficult to see (lower half of Figure 
28A, B).  Between AF and NP, cells in the transition zone were scattered singly or in small 
groups in the dense fibrous matrix (upper part of Figure 28A, B).  The morphology of cells in AF 
and TZ region did not appear to be different between fresh and cultured discs.  The fibrous 
matrix was loose in the NP region when compared to AF. (Figure 29A, B)  The NP cells had 
round cell shapes.  After 2 days of culture in serumless media, NP cells appeared to be separated 
by PG matrix into multiple cell islands. (Figure 29B)      
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 Figure 28A H&E staining of AF and TZ region of fresh disc (200x) 
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Figure 28B H&E staining of AF and TZ region in disc cultured for 2 days in serumless media 
(200x) 
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 NP Cell 
 
Figure 29A H&E staining of NP region in fresh disc (200x) 
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 NP Cell Island 
Figure 29B H&E staining of NP region in disc cultured for 2 days in serumless media (200x) 
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In the NP cultured after 2 dyas in serumless media, approximately 75% of the cells were 
nonviable (Figure 30).  The red staining shows nonviable cells while the green staining 
represents viable cells.  The 2 photon microscopy showed clear images of live and dead cells in 
the NP at 4 random locations (a,b,c,d).  We observed both live and dead cells in the AF and TZ 
regions after one week of culture in serumless, 5%, 10%, and 15% FBS media.  We were not 
able to see the difference in cell viability from different culture condition by this staining 
method.  Also, the staining method was not sensitive enough to test whether cell viability of AF 
and TZ from 1,2,3,4 regions of the disc were different.      
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Figure 30  Cell viability staining in 4 random locations (a,b,c,d) of NP in 2 day culture in 
serumless media (2 photon microscopy) 
 
 
 
 
 
(a) 
(d) (c) 
(b) 
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5.2.2 Outcome Measures 
 
.2.2.1 Disc Metabolism 
 
 NP Composition 
he mean and standard deviation of wet weight and dry weight of NP were 25±5 mg and 4±1 mg 
respectively for fresh discs.  Wet weight and dry weight of NP of fresh discs and discs cultured 
for 2 weeks were not significantly different.  The mean and standard deviation of % hydration of 
the NP was 85%±2% for fresh discs.  % hydration of NP of fresh discs and discs cultured for 2 
weeks were not significantly different.  Other values of the outcome measures are listed in Table 
3.  Results of cultured discs showed no significant changes in the GAG and DNA content in NP 
for different concentration of FBS (Figure 31 and 32).  DNA content of discs in the 15% FBS 
group was significantly higher than other % FBS groups.  Lactate content increased significantly 
with increasing % FBS (p<0.05).  The mean and standard deviation of GAG content of the fresh 
discs was 621±51 µg/mg dry weight, which was not significantly different than the cultured 
discs. The DNA and lactate content of the 15% FBS group were closest to the fresh disc group 
when compared to other % FBS groups (Figure 32 and 33).  GAG, DNA, and lactate data did not 
correlate with each other.  Raw data is included in Appendix E.     
 
 
 
 
 
5
 
•
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Table 3  Mean and standard deviation of outcome measures of fresh and cultured (2 weeks) NP  
NP Wet wt Dry wt 
% 
Hydration GAG DNA Lactate 
 
  (mg) (mg)   (ug/mg) ) (ng/mg (mg/mg) 
Fresh 25±5.0 2 4±1.0 85±2.0 621± 51 1691±56 3.4±2.8 
Serumless 31±1.0 5±0.3 84±0.5 616± 75 1367±105 1.1±0.2 
5% FBS 27±1.0 5±1.0 82±3.0 526± 64 1466±157 1.4±1.8 
10% FBS 32±3.0 6±0.5 82±3.0 581±110 1260±224 3.1±1.6 
15% FBS 25±1.0 4.5±0.5 83±2.0 492± 52 1761±164 3.1±3.6 
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Figure 31  GAG content of NP in fresh and cultured (2 weeks) discs 
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Figure 32  DNA content of NP in fresh and cultured (2 weeks) discs 
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Figure 33  Lactate content in NP of fresh and cultured discs 
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• AF Composition 
 
The mean and standard deviation of wet weight and dry weight of AF were 88±24 mg and 27±8 
mg respectively for fresh discs.  Wet weight and dry weight of AF of fresh discs and discs 
cultured for 2 weeks were not significantly different.  The mean and standard deviation of % 
Hydration of the AF was 70±8% for fresh discs.    % hydration of NP of fresh discs and discs 
cultured for 2 weeks were not significantly different.  Other values of the outcome measures are 
listed in Table 4.  For AF after culture, the GAG content showed no significant difference 
between different % FBS group (Figure 34).  For both DNA and lactate content, there were 
significant increases with increasing % FBS (Figure 35, 36).  The mean and standard deviation 
of GAG content of the fresh discs was 227±90 ug/mg dry weight and the value is not 
significantly different than cultured discs.  The average DNA and lactate content of the cultured 
discs were higher than those in the fresh disc.  DNA and lactate data correlated with each other 
with Pearson correlation coefficient of 0.631. (p<0.01)  There were no correlation observed 
between GAG and DNA or GAG and lactate.  Raw data is included in Appendix E.     
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Table 4  Mean and standard deviation of outcome measures of fresh and cultured AF 
 
AF Wet wt Dry wt 
% 
Hydration GAG DNA Lactate 
  (mg) (mg)   (ug/mg) (ng/mg) (mg/mg) 
Fresh 88±24.0 27±8.0 70±3.0 227±90 218±49 1.6±0.8 
Serumless 99±3.0 30±2.0 70±2.0 200±30 443±121 1.1± 0.2 
5% FBS 78±14.0 24±5.0 69±1.0 204±45 791±80 2.8± 0.7 
10% FBS 81±16.0 26±6.0 70±1.0 255±31 776±105 3.4± 1.0 
15% FBS 84±21.0 26±9.0 70±2.0 208±22 818±81 3.3± 1.5 
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Figure 34  GAG content in AF of fresh and cultured discs  
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Figure 35  DNA content in AF of fresh and cultured discs 
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Figure 36  Lactate content of AF in fresh and cultured discs 
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• Data from Culture Media 
 
Media were collected and GAG and lactate leached out of the disc were measured (Table 5).  
Total GAG in the media ranged 88 to 144 µg/mg, which was about 14% of the total GAG 
produced (tissue + media).  Total lactate in the media ranged 1.2 to 2.2 mg/mg, which was 
around 27% of the total Lactate produced (tissue + media).  Figure 37 and 38 illustrates the 
distribution of GAG and lactate in the media and tissue. 
 
Table 5  GAG and lactate in the media and tissue 
 
GAG (ug/mg) Tissue+Media Total Media  
Lactate 
(µg/mg) Tissue+Media 
Total 
Media 
serumless 903 88  serumless 2.4 1.2 
5% FBS 863 132  5% FBS 6.2 2.0 
10% FBS 963 137  10% FBS 8.5 1.8 
15% FBS 844 144  15% FBS 8.6 2.2 
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             Figure 37  GAG in the culture media and tissue 
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             Figure 38  Lactate in the culture media and tissue 
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5.2.2.2 BMP-2 Measurement  
 
 
Baseline data of BMP-2 in fresh discs were obtained from digested tissue using ELISA.  5 discs 
from one rabbit were used.  The mean and standard deviation of BMP-2 in NP and AF were 
52±20 and 44±12 pg/mg wet weight respectively.  
 
 
5.2.2.3 Marker Gene Transfer 
 
• Ad/lacZ 
 
 
Fifteen discs from 3 rabbits were harvested and cultured for 2 days in serumless media.  Then 
they were injected with Ad/lacZ.  Discs were cultured for 1 more week in media containing 
different % FBS (serumless, 5%, 10%, 10% FBS).  No blue staining was observed after X-gal 
staining in any of the group (Figure 39). 
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 Figure 39  Negative lacZ result after X-gal staining of NP (200x) 
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• Ad/Luciferase 
 
We observed negative from discs injected with Ad/Luciferase.  The luciferase activity in 
Ad/Luciferase group was under 1000 RLU which showed no successful gene transfer (Table 6). 
 
Table 6  Luciferase activity in three experimental groups: positive control, saline control, and 
Ad/Luciferase 
 
Positive Control  
(3ng of Luciferace) 
 
Saline Control 
 
Ad/Luciferase 
1288890 RLU/s 17.3 RLU/s 87.7 RLU/s 
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6.0 DISCUSSION 
 
 
6.1 Comparison with Published Data 
 
 
6.1.1 Part I: Growth Factor and Gene Therapy Study in Cell Culture 
 
 
Our results of rhBMP-2 increases matrix production agrees with study by Yoon T.S, Kim S.K., 
and Li J. on “The effect of bone morphogenietic protein-2 on rat intervertebral disc cells in-
vitro” (2003).  However, AF and TZ of rat disc were used in Yoon’s study while we used human 
NP cells.  In both studies, a dose dependent response was observed.  No published data were 
found on the effect of rhBMP-12 or Ad/BMP-12 on disc cells.    
 
 
6.1.2 Part II: Disc Nutrition Study in Organ Culture 
 
 
Compare to Kazuhiro Chiba’s study74 with adolescent rabbit discs with endplates, our results of 
dry weight and DNA of AF had similar average values.  Their NP dry weight was lower 
compared to our result.  This could be due to different culture condition and difference in rabbit 
age.  Chiba reported mean and standard deviation of dry weight of NP and AF to be 1.5±0.5 and 
20±5 mg/disc after two weeks of culture.  In Chiba’s study, they showed DNA of NP and AF to 
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be 4±2 and 12.5±2.5 µg/disc after one week of culture.  Chiba saw a decrease in NP dry weight 
after two weeks of cultured when compared to that of discs cultured for one week.  In our study, 
we measured dry weight of NP in fresh discs and did not see a significant decrease after two 
weeks of culture.  Chiba did not report data of fresh discs therefore we can not compare their 
results with ours.   
In our study we measured the GAG leached out of from the disc to the media.  The amount 
of GAG leached out during the two weeks culture was a small fraction when compared to GAG 
in the disc.  In Thompson’s study with canine disc tissue26, they reported disc swelling and loss 
of tissue proteoglycan after three or four days of culture.  In our model, the bone-disc-bone 
structure of whole disc culture reduced disc swelling and GAG leaching problem.        
 
 
6.2 New Findings 
 
 
6.2.1 Part I: Growth Factor and Gene Therapy Study in Cell Culture 
 
 
In monolayer culture, rhBMP-2 appeared to be more effective in upregulating matrix synthesis 
than rhBMP-12. Optimal doses for rhBMP-2 and rhBMP-12 were 200ng/ml and 25ng/ml 
respectively. 
 Ad/BMP-12 upregulated matrix synthesis in both NP and AF pellets.  Table 7 shows the 
distribution of increase in matrix synthesis due to increase in cell number and matrix produced 
per cell.  For AF, collagen and non-collagenous protein synthesis was increased largely due to 
cell proliferation.  Increased proteoglycan synthesis was due to both increase in cell number and 
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cell production with equal importance.  For NP, proteoglycan and collagen synthesis was 
upregulated more as a result of increased matrix produced per cell.  Increase of non-collagenous 
protein synthesis in NP pellets was attributed equally to cell proliferation and increase in cell 
production.  
 
Table 7  Distribution of percent increase of matrix synthesis of AF and NP 
 
 
 
 
 
 
 
 
 
 
 
Cell Type 
 
 
Matrix Synthesis 
% of Increase 
Attributed to 
Increase in Cell 
Number 
% of Increase 
Attributed to Increase 
in Matrix Production 
Per Cell 
  Proteoglycan 48% 52% 
AF Collagen 67% 33% 
  Non-Collagenous Protein 88% 12% 
  Proteoglycan 31% 69% 
NP Collagen 34% 65% 
  Non-Collagenous Protein 53% 47% 
 
 
6.2.2 Part II: Disc Nutrition Study in Organ Culture 
 
 
The effect of varying FBS concentration was demonstrated.  No effect on GAG and % hydration 
was observed in the organ culture for NP and AF.  Higher DNA and lactate content was observed 
in higher % FBS for NP and AF.  In AF, DNA and lactate content data correlate with each other.  
The correlation between AF DNA and lactate means that the cell metabolism depends on amount 
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of cells.  When %FBS increased, we observed an increase in DNA as well as an increase in 
lactate.  When there is more DNA, there are more cells.  Therefore more glucose is needed and 
they are utilized and producing more lactate.  Originally, half of the cultured discs was injected 
with Ad/BMP-2 (6x106 PFU) one week days after the culture, and then it was cultured for 
another week.  The other half was injected with 10 µl of saline as control.  Appendix E showed 
disc levels injected with saline or Ad/BMP-2.  However, no significant result was observed 
between the two groups.  Therefore, we combined the data.    
 
 
6.2.3 Energy Cost of Gene Therapy: A Theoretical Analysis 
 
In Part I of the study on gene therapy, we observed matrix synthesis of disc cells increased after 
treated with Ad/BMP-12.  Pellets were cultured in serumless media, which were minimal 
nutrients for cell survival.  We did not observe any negative effects of gene transfer on disc cells 
such as cell death.  Total DNA content of pellets increased after treated with Ad/BMP-12, and 
matrix synthesis per cell also increased.  If the energy cost of gene transfer was high, then cells 
should not have sufficient energy to survive or even proliferate.  Therefore, Part I of the study 
showed that successful gene transfer did not affect cell viability, implying that the energy cost of 
gene transfer is low compared to energy cost of basic cell functions. 
 In Part II of the study on organ culture, we could not transduce the disc cells due to low 
cell viability.  In this case, the cell death could be due to lack of nutrients in the NP.  The cell 
death in NP was not caused by gene transfer.  If we have sufficient nutrients in the disc for cells 
to survive, then we should be able to transduce the cells.     
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6.3 Limitations 
 
 
6.3.1 Part I: Growth Factor and Gene Therapy Study in Cell Culture 
 
 
The rhBMP-2, rhBMP-12, and Ad/BMP-12 study was done in an in-vitro environment.  We do 
not know if we can achieve the same result in the in-vivo condition.  The optimal dose found in 
the in-vitro setting will be different than that in the in-vivo condition.  Therefore, the next step 
should be to investigate the effect of Ad/BMP-12 in an animal model.  In the growth factor 
study, we only tested rhBMP-2 up to 300 ng/ml and rhBMP-12 to 100 ng/ml.  It was not 
practical to test too many different concentrations.  Therefore, we cannot conclude what the 
optimal dose of rhBMP-2 and rhBMP-12 is.  To do so, a wider range of doses should be studied.  
We might see higher matrix synthesis at higher doses or toxic effects when doses are too high.  
Another limitation of the study is that we assumed all well plates of cells or pellets responded 
similarly to the stimuli.  Different well plates of cells or different pellets were used for various 
assays such as cell count, DNA, PG, collagen, and non-collagenous protein synthesis.  The best 
and most accurate way to normalize our data is to use the same well plate or pellet for 
measurement of matrix synthesis and cell count or DNA content.  However, it was not possible 
to conduct different assays on the same sample. 
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6.3.2 Part II: Disc Nutrition Study in Organ Culture 
 
 
In the organ culture study, healthy rabbit discs were chosen for the animal model.  The results 
will be different from the degenerated human discs.  Also, the study is in-vitro, therefore there is 
no fluid flow in the disc culture from movement as in the in-vivo condition. 
In the statistical analysis, the assumption of that discs from different rabbit was the same 
was made due to small sample size.  We did not have sufficient number of rabbit per experiment 
group to test whether there was an inter-rabbit effect.  However, we did investigate and found 
that intra-rabbit effect was very small on disc weight, % hydration, DNA, and lactate when 
compared to the effect of different % FBS.  Therefore we can neglect differences between discs 
from different levels.   
The main limitation of the current culturing method is the difficulty in maintaining the 
cell viability in the NP and the inability to transduce cells in the culture.  In order to study the 
effect of gene transfer on disc metabolism, successful gene transfer needs to be achieved in the 
organ culture.  Other culture method such as mono-layer or pellet culture can be considered to 
investigate the effect of gene transfer on cell metabolism.  
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6.4 Conclusions 
 
 
6.4.1 Part I: Growth Factor and Gene Therapy Study in Cell Culture 
 
 
RhBMP-2 and rhBMP-12 both upregulated proteoglycan, collagen, and non-collagenous protein 
synthesis by NP cells in monolayer culture, although rhBMP-2 demonstrated a more substantial 
anabolic effect on matrix production.  We observed a dose dependent response to rhBMP-2 in 
NP cells.  RhBMP-12 demonstrated the potential for matrix synthesis in NP cells.  RhBMP-12 
upregulated PG, collagen and non-collagenous protein synthesis in NP cells. In AF cells, only 
non-collagenous protein synthesis was increased after treating with rhBMP-12.  Ad/BMP-12 
increased AF cell proliferation and matrix synthesis per cell, which resulted in an overall 
increase in total matrix production.  PG, collagen, and non-collagenous protein synthesis 
increased in AF pellets treated with Ad/BMP-12.  The increased collagen synthesis may help 
maintain the structural integrity and mechanical strength of the disc.  We observed increase in 
cell number in pellets treated with Ad/BMP-12.  It is an exiting possibility to combine Ad/BMP-
12 with adeno-virus carrying other growth factor genes to treat IDD. 
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6.4.2 Part II: Disc Nutrition Study in Organ Culture 
 
 
In the organ culture, % FBS in the medium did not significantly affect % hydration and GAG 
content of NP or AF during the two weeks duration of the study.  In NP, DNA content was 
higher in the 15% FBS group and the lactate content increased with increasing % FBS.  In AF, 
DNA and lactate both increased with increasing % FBS.  There is a positive correlation between 
the DNA and lactate in AF.  The flow chart below shows possible relations between DNA and 
lactate content with increasing % FBS:     
 
% FBS Nutrient 
available 
DNA 
content 
ATP required Glucose 
used 
Lactate 
produced 
 From the result of administering Ad/lacZ and Ad/Luciferase, we did not achieve 
successful gene therapy in the organ culture possibly due to low cell viability.     
 
 
 
 
 
 
 
 96
  
6.5 Future Directions 
 
 
6.5.1 Part I: Growth Factor and Gene Therapy Study in Cell Culture 
 
 
There is an urgent need for less-invasive therapies for IDD that aim to treat or prevent the 
disease. In order to provide more treatment options for patients and to advance our knowledge in 
medicine, there is a need for basic science research.  In this study, we have demonstrated the 
potential of Ad/BMP-12 to upregulate matrix synthesis of cells from degenerated discs in an in-
vitro setting. The next step will be to study the effects of Ad/BMP12 in an in-vivo setting in an 
animal model of IDD.    
 
 
6.5.2 Part II: Disc Nutrition Study in Organ Culture 
 
 
Further studies should focus on attempts to achieve successful gene therapy in the organ culture 
as well as to study the effect of gene therapy on disc nutrition in other in-vitro culture such as 
monolayer or pellet culture.  One possible reason for unsuccessful gene transfer was low cell 
viability.  To address this issue, different culture method, culture medium, and time of injection 
needs to be reconsidered.  Also, applying mechanical loads to discs to mimic in-vivo condition 
may improve disc nutrition in the organ culture.  
An alternative to using organ culture to study effect of gene therapy is the use of other 
culture method such as mono-layer or pellet culture.  Future research on finding the lowest 
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concentration of glucose to increase matrix synthesis by gene transfer can be helpful in 
understanding the energy demand of gene transfer.  Another area of interest is to investigate the 
oxygen consumption of cells with and without gene transfer.  This study will allow us to 
determine if the oxygen demand increases when cells are producing more matrixes after gene 
transfer.  Due to the great cost and suffering of back pain, extensive research is needed to further 
improve our understanding in effects of potential treatments such as gene therapy in order to 
successfully treat or prevent the IDD and improve the quality of life.   
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APPENDICES 
 
 
Appendix A  Part I: Growth Factor Study in NP Cell Culture 
 
Table 8  Effect of rhBMP-2 on PG in NP monolayer 
Proteoglycan Synthesis in NP          
Group control BMP-2 25 
BMP-2 
50 
BMP-2 
100 BMP-2 200 
BMP-2 
300 
Sample 104 116 103 131 584 402
  95 105 110 150 446 555
  100 132 91 115 549 526
  113 174 185 270 614 707
  102 201 140 302 503 691
  85 169 183 277 586 577
  98 240 215 260 515 550
  102 207 324 254 630 646
  121 347 178 439 204 260
  99 277 242 340 192 251
  79 280 236 349 190 253
  91 201 227 474 200 237
  86 171 286 402 206 240
  123 198 174 417 192 244
  94 166 151 450 241 245
  104 143 139 316 171 182
  106 146 154 404 204 260
  96 145 128 395 194 267
  92 131 159 484 202 197
  96 138 125 391 216 236
  107 160 134 409 468 468
  94 144 160 494 505 505
  93 138 139 157     
  94 129 301 175     
  102 425 232 140     
  124 275 236 182     
  104 395   169     
  93     163     
  99     172     
  103     147     
  98     148     
        141     
        468     
        505     
 100
 
Table 8 (continued) 
  
 control BMP-2 25 
BMP-2 
50 
BMP-2 
100 BMP-2 200 
BMP-2 
300 
Mean 100 198 183 297 355 386
S.D. 10 84 62 132 178 178
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Table 9  Effect of rhBMP-12 on PG synthesis in NP monolayer  
Proteoglycan Synthesis in NP    
Group BMP-12 25 BMP-12 50 BMP-12 100 
Sample 89 131 91
  78 99 89
  73 112 90
  150 147 125
  140 120 141
  178 134 113
  179 162 128
  165 171 139
  150 128 123
  145 84 160
  126 75 106
  156 85 125
  110 114 112
  90 114 135
  87 113 152
  146 131 227
  154 142 214
  148 118 229
  169 139 212
  181 153 233
  161 121 223
  152 165 214
  171 117 218
  164 145 176
  137 122 196
  131 129 111
  134 105 196
    123 135
    
    
  BMP-12 25 BMP-12 50 BMP-12 100 
Mean 139 125 158
S.D. 32 24 49
 
Average Proteoglycan synthesis in NP for control is 140 pico mol S per sample 
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Table 10  Effect of rhBMP-2 on collagen synthesis in NP monolayer 
Collagen Content in NP         
Group control BMP-2 25 
BMP-2 
50 
BMP-2 
100 
BMP-2 
200 
BMP-2 
300 
Sample 89 226 225 284 526 639 
  104 250 198 341 542 592 
  102 277 289 330 490 377 
  105 278 270 306 549 533 
  92 139 217 283 786 569 
  101 172 224 291 584 575 
  110 160 210 296 573 661 
  97 152 189 355 611 581 
  116 115 141 236 184 235 
  97 112 100 197 232 209 
  99 170 161 142 154 163 
  88 131 90 151 244 173 
  76 169 180 293 181 160 
  108 139 190 181 172 125 
  104 126 164 169 160 122 
  111 130 180 204 217 106 
  91 168 192 486 175 122 
  94 144 120 307 98 111 
  93 122 164 334 134 101 
  123 104 165 540 116 120 
  121 94 128 366 241 203 
  78 117 118 513 372 313 
  101 149 185 301 357 301 
  110 118 136 132 413 348 
  123 165 114 138     
  131 251 222 182     
  97 236 259 145     
  87 288 232 147     
  88 196 171 148     
  81     224     
  97     191     
  87     230     
  116     238     
  99     367     
  100     353     
  84     408     
       
       
  control BMP-2 25 
BMP-2 
50 
BMP-2 
100 
BMP-2 
200 
BMP-2 
300 
Mean 100 169 180 272 338 310 
S.D. 13 57 50 108 198 201 
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Table 11  Effect of rhBMP-12 on collagen synthesis in NP monolayer 
Collagen 
Synthesis 
in NP       
BMP-12 
25 
BMP-12 
50 
BMP-12 
100 Group 
Sample 132 123 156
  149 112 154
  195 115 170
  156 117 135
  151 179 149
  126 142 169
  139 174 170
  156 155 156
  109 168 149
  130 124 124
  149 146 143
  96 153 100
  136 163 118
  145 229 108
  198 192 179
  110 183 63
  134 107 171
  249 124 231
  74 68 83
  166 174 107
  178 70 75
  63 183 76
  153 186 86
  150 139 116
  155 155 101
  116 138 166
  145 133 213
  136 109 155
      183
    
    
  
BMP-12 
25 
BMP-12 
50 
BMP-12 
100 
Mean 143 145 138
S.D. 37 37 42
 
Average collagen synthesis in NP for control is 2159 counts per minute (CPM) 
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Table 12  Effect of rhBMP-2 on non-collagenous protein synthesis in NP monolayer 
 
Non-collagenous protein synthesis in NP       
Group control BMP-2 25 BMP-2 50 BMP-2 100 BMP-2 200 BMP-2 300 
Sample 89 226 225 284 340 321 
  104 250 198 341 279 452 
  102 277 289 330 308 189 
  105 278 270 306 269 304 
  92 139 217 283 358 426 
  101 172 224 291 306 338 
  110 160 210 296 303 333 
  97 152 189 355 306 341 
  116 143 129 176 136 170 
  107 131 83 228 167 147 
  101 162 116 192 139 134 
  75 131 93 178 151 114 
  96 203 188 190 150 132 
  106 163 157 149 139 123 
  115 147 127 181 141 126 
  83 150 143 219 149 148 
  88 110 108 218 166 147 
  82 111 116 251 162 172 
  99 121 103 246 72 163 
  84 130 97 260 241 246 
  107 128 109 278 394 402 
  107 119 112 233 323 330 
  132 126 113 270 378 386 
  75 143 121 104     
  101 109 122 139     
  92 208 195 140     
  105 215 221 170     
  99 257 245 148     
  89 238 195 121     
  116     104     
  108     135     
  114     224     
  118     367     
  96     300     
  98     352     
  88           
       
       
  control BMP-2 25 BMP-2 50 BMP-2 100 BMP-2 200 BMP-2 300 
Mean 100 169 163 230 234 245 
S.D. 12 53 58 76 96 113 
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Table 13  Effect of rhBMP-12 on non-collagenous protein synthesis in NP monolayer 
Non-collagenous protein synthesis in NP 
Group BMP-12 25 BMP-12 50 BMP-12 100 
Sample 132 123 156
  149 112 154
  195 115 170
  156 117 135
  151 179 149
  126 142 169
  139 174 170
  156 155 156
  137 177 137
  144 167 116
  150 156 116
  129 141 80
  216 135 100
  172 181 90
  190 168 177
  129 203 57
  175 96 171
  164 91 168
  177 121 179
  176 98 159
  135 137 187
  185 105 172
  142 92 176
  184 107 157
  202 135 151
  154 136 142
  195 172 177
  192 135 134
      162
    
    
  BMP-12 25 BMP-12 50 BMP-12 100 
Mean 163 138 147
S.D. 26 31 32
 
 
Average non-collagenenous protein synthesis in NP for control is 5981 CPM 
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Appendix B  Part I: Growth Factor Study in AF Cell Culture 
 
 
Table 14  Effect of RhBMP-2 and rhBMP-12 on PG synthesis in AF monolayer 
Proteoglycan synthesis in AF           
Group control BMP2 25 
BMP2-
50 
BMP2-
100 
BMP12-
25 
BMP12-
50 
BMP12-
100 
Sample 126 121 94 95 103 97 102 
  93 92 88 100 101 95 108 
  81 88 119 106 98 109 91 
  121 113 116 118 88 98 104 
  88 81 87 85 104 100 95 
  90 106 97 97 109 102 101 
  100 100 131 103 94 96 134 
  96 105 85 84 104 119 76 
  113 95 85 113 103 86 91 
  91       97 87 88 
  96       91 75 96 
  115       101 73 95 
  86       89 72 94 
  100       98 75 89 
  98       95 73 104 
  96       110 110 120 
  114       80 115 75 
  88         120   
  97         125   
        
        
  control BMP2 25 
BMP2-
50 
BMP2-
100 
BMP12-
25 
BMP12-
50 
BMP12-
100 
mean 100 100 100 100 98 96 98 
sd 13 13 17 12 8 17 14 
 
 
 
Average Proteoglycan synthesis in AF for control is 289.38 pico mol S per sample 
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Figure 40  PG synthesis in AF treated with rhBMP-2 
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Figure 41  PG synthesis in AF treated with rhBMP-12 
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Table 15  Effect of rhBMP-2 and rhBMP-12 on collagen synthesis in AF monolayer 
Collagen Synthesis in AF (% 
of control)           
Group control BMP2-25 BMP2-50 BMP2-100 BMP12-25 BMP12-50 BMP12-100 
Samples 102 119 72 192 135 59 146
  94 63 86 123 57 62 52
  85 55 59 106 91 88 113
  119 155 111 115 139 59 88
  125 81 108 101 135 55 79
  70 84 39 105 91 73 85
  93 94 34 91 69 48 110
  113 111 59 60 59 103 75
  115 134 148 131 148 114 122
  111 122 81 120 130 111 152
  118 123 120 125 130 135 105
  56 153 115 184 158 135 126
  114       112 97 104
  118       99 111 80
  101       109 101 82
  99       101 99 104
  105       101 109 112
  89       91 109 104
  97       109 93 91
  95       103 67 114
  81       88     
        
        
  control BMP2-25 BMP2-50 BMP2-100 BMP12-25 BMP12-50 BMP12-100 
Mean 100 108 86 121 108 91 102
S.D. 17 33 35 36 28 26 24
 
Average collagen synthesis in AF for control is 11989.3 CPM 
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 Figure 42 Collagen synthesis in AF by rhBMP-2 
 
 
 
Collagen Sy nthes is  in Anulus  Fibrosus  Cells  by  rh
BMP12
0
50
100
150
control BMP12-25 BMP12-50 BMP
ng/ml
Pe
rc
en
t o
f c
on
tro
l
 Figure 43  Collagen synthesis in AF by rhBMP-12 
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Table 16  Effect of rhBMP-2 and rhBMP-12 on non-collagenour protein synthesis in AF 
monolayer 
Non-collagenenous Protein Synthesis in AF 
(percent of control)         
Group control BMP2-25 BMP2-50 BMP2-100 BMP12-25 BMP12-50 BMP12-100 
Samples 100 138 77 165 137 53 133
  96 47 85 114 62 65 128
  84 44 55 89 88 72 93
  121 120 95 111 123 60 70
  109 96 161 195 154 104 161
  90 178 45 147 127 77 119
  73 159 43 247 111 116 180
  128 195 65 257 201 127 79
  101 124 121 105 152 127 111
  133 122 86 111 125 96 143
  109 116 126 121 136 118 107
  57 128 124 155 142 117 113
  90       87 107 119
  98       114 107 139
  118       115 124 123
  92       101 112 111
  97       123 102 121
  91       133 136 156
  96       102 149 129
  118       109 159 136
            185 193
        
        
  control BMP2-25 BMP2-50 BMP2-100 BMP12-25 BMP12-50 BMP12-100 
Ave 100 122 90 151 122 110 127
s.d. 18 45 37 56 29 33 30
 
Average non-collagenenous protein synthesis in AF for control is 15224.7 CPM 
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Appendix C  Part I: Gene Therapy Study in NP Pellet Culture 
 
 
Table 17  Effect of Ad/BMP-12 on DNA content in NP pellets 
DNA Content in NP       
Group control 50MOI of BMP-12 100MOI of BMP-12 150MOI of BMP-12 
Sample 87 201 186 195
  94 314 215 233
  107 218 218 198
  109 185 182 181
  106 184 182 182
  97 192 200 227
     
     
Concentration control 50MOI of BMP-12 100MOI of BMP-12 150MOI of BMP-12 
Mean 100 216 197 203
S.D. 8 50 16 22
 
Average DNA content in NP is 84.4 ng/pellet 
 
 
 
DNA Content in NP Pellets Synthesized by Ad-BMP-12 (6 samples)
0
50
100
150
200
250
300
control 50MO
Pe
rc
en
t o
f c
on
tro
l
  
Figure 46  DNA content in NP pellets b
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Table 18  Effect of Ad/BMP-12 on PG synthesis in NP pellet (before normalization) 
PG synthesis in NP pellet     
  Not Normalized by DNA Content   
Group control BMP12 50 BMP12 100 BMP12 150  
Sample 79 383 354 461
  88 349 394 354
  98 398 419 501
  92 379 411 401
  102 433 450 453
  149       
  84       
  142       
  86       
  82       
     
     
  control BMP12 50 BMP12 100 BMP12 150  
Mean 100 388 406 434
S.D. 25 31 35 57
 
 
Table 19  Effect of Ad/BMP-12 on PG synthesis in NP pellet (after normalization) 
PG synthesis in NP pellet     
  Normalized by DNA Content   
Group control BMP12 50 BMP12 100 BMP12 150  
Sample 79 177 180 228
  88 162 200 175
  98 184 213 248
  92 175 209 198
  102 200 228 224
  149       
  84       
  142       
  86       
  82       
     
     
  control BMP12 50 BMP12 100 BMP12 150  
Mean 100 180 206 215
S.D. 25 14 18 28
 
Averaged PG for NP control is 55.95 pico mol S per pellet 
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Table 20  Effect of Ad/BMP-12 on collagen synthesis in NP pellet (before normalization) 
Collagen Content before Normalization   
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 80 305 430 340
  116 295 315 365
  103 431 360 293
  105 347 377 302
  113 401 437 349
  103 322 359 360
  78 347 384 223
  92 391 561 389
  71 394 358 405
  98 398 348 338
  105 416 340   
  87 409 318   
  125       
  92       
  106       
  119       
  94       
  106       
  86       
  123       
     
     
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 371 382 336
S.D. 15 46 68 53
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Table 21  Effect of Ad/BMP-12 on collagen synthesis in NP pellet (after normalization) 
Collagen Content after Normalization     
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 80 141 218 168
  116 137 160 181
  103 199 183 145
  105 160 192 149
  113 185 222 173
  103 149 182 178
  78 161 195 110
  92 181 285 193
  71 182 182 200
  98 184 177 167
  105 193 173   
  87 189 161   
  125       
  92       
  106       
  119       
  94       
  106       
  86       
  123       
     
          
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 172 194 166
S.D. 15 21 34 26
 
Average collagen of NP control is 790.55 CPM  
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Table 22  Effect of Ad/BMP-12 on non-collagen synthesis in NP pellet (before normalization) 
Non-collagenous protein before normalization   
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 94 274 248 260
  101 288 225 296
  98 285 281 238
  92 255 264 286
  98 293 284 290
  93 268 297 286
  97 303 306 239
  101 373 448 330
  105 303 323 310
  103 230 275 411
  106 258 264   
  95 254 284   
  104       
  98       
  105       
  98       
  92       
  126       
  95       
  99       
     
    BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 282 292 295
S.D. 8 36 56 50
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Table 23  Effect of Ad/BMP-12 on non-collagen synthesis in NP pellet (after normalization) 
Non-collagenous protein after normalizaion   
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 94 127 126 129
  101 134 114 146
  98 132 142 118
  92 118 134 142
  98 136 144 144
  93 124 151 142
  97 140 155 118
  101 173 227 164
  105 140 164 153
  103 107 140 203
  106 120 134   
  95 118 144   
  104       
  98       
  105       
  98       
  92       
  126       
  95       
  99       
     
     
    BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 131 148 146
S.D. 8 17 28 25
 
Average non-collagenous protein of NP control is 4686.9 CPM 
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Appendix D  Part I: Gene Therapy Study in AF Pellet Culture 
 
Table 24  Effect of Ad/BMP-12 on DNA content of AF pellets 
Mean DNA 
content of AF 
pellets         
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean  
(ng DNA 
/pellet) 62 129 138 123
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 Figure 42  DNA content of AF treated with Ad/BMP-12  
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Table 25  Effect of Ad/BMP-12 on PG synthesis in AF pellets (before normalization) 
PG in AF pellets before DNA normalization   
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 84 417 272 276
  101 327 347 235
  96 307 275 263
  107 324 273 267
  100 317 256 260
    323 302 310
     
     
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 336 287 269
S.D. 8 37 30 22
 
 
 
 
 
Table 26  Effect of Ad/BMP-12 on PG synthesis in AF pellets (after normalization) 
PG in AF after DNA normalization     
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 84 201 123 139
  101 157 156 119
  96 148 124 133
  107 156 123 135
  100 153 115 131
    155 136 156
     
     
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 161 129 136
S.D. 8 19 15 12
 
Average PG for AF control is 55.94 pico mol S per pellet 
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Table 27  Effect of Ad/BMP-12 on collagen synthesis in AF pellets (before normalization) 
Collagen Content in AF before DNA normalization   
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 105 437 150 412
  109 243 441 365
  86 232 148 412
  106 293 303 321
  94 220 291 251
  100 189 274 221
      369 187
      323 136
      281 305
      245 253
        176
        276
     
     
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 269 282 276
S.D. 9 89 89 90
 
 
Table 28  Effect of Ad/BMP-12 on collagen synthesis in AF pellets (before normalization) 
Collagen Content in AF after DNA normalization   
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 105 210 68 207
  109 117 199 183
  86 112 66 207
  106 141 137 162
  94 106 131 126
  100 91 123 111
      166 94
      145 68
      127 153
      110 127
        88
        139
     
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 129 127 139
S.D. 9 43 40 45
 
Average collagen synthesis in control AF is 1284 CPM 
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Table 29  Effect of Ad/BMP-12 on non-collagen synthesis in AF pellets (before normalization) 
Non-collagenous protein in AF before DNA normalization 
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 90 237 184 213
  97 226 249 225
  109 224 185 226
  103 211 203 231
  100 224 232 190
   213 223 159
      232 168
      246   
      234   
     
     
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 222 221 202
S.D. 7 9 25 29
 
 
 
Table 30  Effect of Ad/BMP-12 on non-collagen synthesis in AF pellets (after normalization) 
Non-collagenous protein in AF after DNA normalization 
Group control BMP-12 50 BMP-12 100 BMP-12 150 
Sample 90 114 83 108
  97 109 112 114
  109 108 84 114
  103 102 91 117
  100 108 105 96
    102 101 81
     104 85
      111   
      106   
     
     
  control BMP-12 50 BMP-12 100 BMP-12 150 
Mean 100 107 100 102
S.D. 7 5 11 15
 
 
Average non-collagenous synthesis in control AF is 5730.8 CPM 
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Appendix E  Part II: Disc Nutrition Study in Organ Culture (NP Outcome Measures) 
 
 
 
Table 31  Outcome measures of NP in fresh and cultured discs (2 week culture) 
NP 
Disc 
Level Wet wt Dry wt % Hydration GAG DNA Lactate 
    mg mg   ug/mg ng/mg mg/mg 
fresh L1-L2 30.7 4.3 86 548 1284 3.3 
  L2-L3 17.9 3 83 663 1407 0.6 
  L3-L4 26.1 3.5 87 679 1671 4.6 
  L4-L5 28.3 5.2 82 621 1040 1.6 
  L5-L6 26.6 4.5 83 670 1069 0.3 
  L1-L2 30.6 4.7 85 553 1958 5.2 
  L2-L3 19.7 2.6 87 606 2297 2.7 
  L3-L4 16.6 2.2 87 585 2702 9.4 
  L4-L5 26.2 4.4 83 663 1789 2.8 
serumless L1-L2* 30.9 4.8 84 559 1504 0.0 
  L2-L3 29.1 4.6 84 541 1409 0.0 
  L3-L4* 29.7 5 83 612 1291 0.0 
  L4-L5 32.1 5.5 83 639 1236 0.5 
  L5-L6* 30.8 5 84 730 1397 0.0 
5% FBS L1-L2 27.6 4.4 84 520 1495 3.6 
  L2-L3* 28.2 4.8 83 440 1463 0.0 
  L3-L4 26.8 4.9 82 589 1646 2.1 
  L5-L6* 26 5.8 78 555 1263 0.0 
10% FBS L1-L2* 32.6 5.1 84 530 1591 1.4 
  L2-L3 33.3 5.2 84 467 1391 5.6 
  L3-L4* 32.5 5.6 83 760 1128 3.6 
  L4-L5 33.1 6.1 82 585 1125 2.2 
  L5-L6* 27.3 6 78 563 1066 2.7 
15% FBS L1-L2 25.2 3.9 85 535 1916 0.0 
  L2-L3* 26.3 4.3 84 419 1820 7.2 
  L3-L4 23.7 4.6 81 494 1778 5.0 
  L4-L5* 25.8 5.2 80 521 1531 0.0 
 
* Injected with Ad/BMP-2 (6x106 PFU) one week after culture, then cultured for one more week      
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Appendix F  Part II: Disc Nutrition Study in Organ Culture (AF Outcome Measures) 
 
 
Table 32  Outcome measures of AF in fresh and cultured discs (2 week culture) 
AF 
Disc 
Level Wet wt Dry wt % Hydration GAG DNA Lactate 
    mg mg         
fresh L1-L2 88.8 22.2 75 226 198 0.1 
  L2-L3 70.2 19.9 72 194 122 3.0 
  L3-L4 99.1 30.8 69 265 289 1.9 
  L4-L5 94.9 30.4 68 193 248 1.7 
  L5-L6 136 42.4 69 228 214 1.4 
  L1-L2 100.2 34.5 66 146 184 1.0 
  L2-L3 53.7 16.8 69 155 243 2.0 
  L3-L4 80 24.1 70 195 208 1.7 
  L4-L5 69.9 18.9 73 446 259 1.8 
serumless L1-L2 94.2 27.9 70 150 238 1.2 
  L2-L3 102.8 28.6 72 201 451 1.3 
  L3-L4 96.8 30.1 69 211 462 1.1 
  L4-L5 98.9 30.9 69 228 545 1.1 
  L5-L6 100.5 32.4 68 211 519 0.8 
5% FBS L1-L2 66.2 20.9 68 134 796 3.3 
  L2-L3 66.1 19.7 70 223 703 3.4 
  L3-L4 87.8 27 69 228 895 2.1 
  L5-L6 92.8 29.9 68 231 771 2.3 
10% FBS L1-L2 65.7 19.2 71 247 823 3.6 
  L2-L3 64.9 19.2 70 210 751 4.7 
  L3-L4 87.5 25.8 71 251 935 3.8 
  L4-L5 103.8 32.5 69 289 670 2.5 
  L5-L6 84.5 26.2 69 278 703 2.2 
15% FBS L1-L2 62.4 17.8 71 215 806 1.8 
  L2-L3 71.1 19.6 72 186 714 5.4 
  L3-L4 93.3 30.3 68 236 908 3.3 
  L4-L5 108.6 36.1 67 196 844 2.7 
 
 
 
 
 
 
 
 
 124
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
1 Lipson S.J.: “Aging Versus Degeneration of the Intervertebral Disc.”  The Lumbar Spine, Ed 
by JN Weinstein and SW Wiesel. Philadelphia, W.B. Saunders Company, (1990), pp. 261-265. 
 
2 Giot B., Fessler R., Molecular Biology of Degenerative Disc Disease, Neurosurgery, Vol. 
47(5), (2000), pp. 1034-1040.  
 
3 Antoniou J., Goudsouzian N., Terrence F., Winterbottom N., Steffen T., Poole A.R., Aebi M., 
Alini M. The Human Lumbar Endplate: Evidence of Changes in Biosynthesis and Denaturation 
of the Extracellular Matrix with Growth, Maturation, Aging, and Degeneration, Spine, Vol. 
21(10), (1996), pp. 1153-1161. 
 
4 Kang J.D., Stefanovic-Racic M., McIntyre L.A., Georgescu H.I., Evans C.H., Toward a 
Biochemical Understanding of Human Intervertebral Disc Degeneration and Herniation: 
Contributions of Nitric Oxide, Interleukin-6, and Prostaglandin E2, Spine, Vol. 21, (1996), pp. 
1065-1073) 
 
5 Lipson S.J., Muir H., 1980 Volvo Award in Basic Science: Proteoglycans in Experimental 
Intervertebral Disc Degeneration, Spine, Vol. 6, (1981), pp194-210. 
 
6 Garfin S.R., Herkowitz, “The Intervertebral Disc: Disc Disease – Does It Exist?.” The Lumbar 
Spine, Ed by JN Weinstein and SW Wiesel, Philadelphia, W.B. Saunders Company, (1990), 
pp. 369-380. 
 
7 Nachemson A.L., Jonsson E., Neck and Back Pain: The Scientific Evidence of Causes,  
Diagnosis, and Treatment, Philadelphia, Lippincott Williams and Wilkins, (2000), pp. 79-126. 
 
8 Deyo R.A., Cherkin D., Conrad D, Volinn E., Cost, controversy, crisis: Low back pain and the 
health of the public. Annu Rev Public Health , Vol. 12, (1991), pp. 14156. 
 
9 Oshima H, Ishihara H, Urban JPG, Tsuji H. The Use of Coccygeal Discs to Study Intervertebral 
Disc Metabolism. Journal of Orthopaedic Research, Vol. 11,(1993); 11:332-338 
 
 
 126
 
10 Musculoskeletal Conditions in the United States by American Academy of Orthopaedic 
Surgeons (AAOS), (1999).   
 
11 Frymoyer J.W., Cats-Baril W.L. An overview of the incidences and costs of low back pain.  
Orthop Clin North Am, Vol. 22, (1991), pp. 26371. 
 
12 Kelsey JL, Mundt DF, Golden AL: “Epidemiology of low back pain.” The Lumbar Spine and 
Back Pain, Ed by Jayson MIV, Churchill Livingsone, (1992) , pp537-549. 
 
13 Andersson G.B.J.: “Epidemiology”, Essentials of the Spine. Ed. Weinstin JN, Rydevik BL, 
Sonntag VKH, New York, Raven Press, (1995). 
 
14 Praemer A., Furner S., Rice D.P.: Musculoskeletal conditions in the United States. Illinois: 
American Academy of Orthopaedic Surgeons, (1992), pp 23-33. 
 
15 Boden S.D., Wiesel S.W., Wolfe R.M.: “Standardized Approaches to the Diagnosis and 
Treatment of Low Back Pain and Multiply Operated Low Back Patients”, Low Back Pain, Ed. 
By Wolfe R.M., Borenstein D.G., Wiesel S.W, Matthew Bender & Company, Inc., (2000), pp 
93-157. 
 
16 Borenstein D.G., Wiesel S.W., Boden S.D.: “Medical Diagnosis and Comprehensive 
Management”, Low Back Pain, WB Saunders Company, (1995), pp595-650. 
 
17 Boden S.D., Wiesel S.W., Laws E.R., Rothman R.H.: The Aging Spine: Essentials of 
Pathophysiology, Diagnosis, and Treatment, W.B. Saunders Company, (1991), pp 3-38, 167-
189. 
 
18 Spinal Fusions in the United States by American Academy of Orthopaedic Surgeons (AAOS), 
(1999) 
 
19 Boden S.D.: Fusion: Biology of Lumbar Spine Fusion and Bone Graft Materials, Ed by JN 
Weinstein and SW Wiesel. Philadelphia, W.B. Saunders Company, (1996), pp 1284-1306. 
 
20 Esses S.I., Textbook of Spinal Disorders, J.B. Lippincott Company, (1995), pp135-172. 
 
21 Gruber H.E., Leslie K.P., Ingram J.A., Autologous Intervertebral Disc Cell Implantation: A 
Model Using Psammomys Obesus, the Sand Rat, Spine, Vol. 27, (2002), pp. 1626-33. 
 
22 Hutton W.C., Meisel H.J., Akamaru T., Autologous Disc Chondrocyte Transplantation for 
Repair of Acute Disc Herniation (Abstract), North American Spine Society, 16th Annual 
Meeting, Seattle, WA; 2001. 
 
 
 127
 
23 Okuma J., Mochida J., Nishimura K, Reinsertion of Stimulated Nucleus Pulposus Cells 
Retards Intervertebral Disc Degeneration: an In-vitro and in-vivo Experimental Study. J 
Orthop Res, Vol. 18, (2000), pp988-97. 
 
24 Aguiar D.J., Johnson S.L., Oegema T.R., Notochordal Cells Interact with Nucleus Pulposus 
Cells: Regulation of Proteoglycan Synthesis. Exp Cell Res, Vol. 246, (1999), pp. 129-37. 
 
25 Thompson J.P., Oegema T.R. Jr., Bradford D.S., “Stimulation of mature canine intervertebral 
disc by growth factors”, Spine, Vol. 16, (1991), pp. 253-260. 
 
26 Nishida K., Kang J.D., Gilbertson L.G., Moon S.H., Suh J.K., Vogt M.T., Robbins P.D., Evans 
C.H., “Modulation of the Biologic Activity of the Rabbit Intervertebral Disc by Gene Therapy: 
An In Vivo Study of Adenovirus-Mediated Transfer of the Human Transforming Growth 
Factor beta-1 Encoding Gene”, Spine, Vol. 24, (1999), pp. 2419-2415. 
 
27 Moon S.H., Gilbertson L.G., Nishida K., Knaub M., Muzzonigro T., Robbins P.D., Evans 
C.H., Kang J.D., Spine, Vol. 25, (2000); 25, pp. 2573-2579. 
 
28 Hecht B.P., Fischgrund J.S., Herkowitz H.N, “The use of recombinant human bone 
morphogenetic protein 2 (rhBMP-2) to promote spinal fusion in a nonhuman primate anterior 
interbody fusion model”, Spine, Vol. 24, (1999), pp. 629-36. 
 
29 Wozney J.M., Rosen V., “Bone morphogenetic protein and bone morphogenetic protein gene 
family in bone formation and repair”, Clin Orthop, Vol. 346, (1998), pp. 26-37. 
 
30 Yoon T.S., Kim S.K., Li J., “The effect of bone morphogenetic protein-2 on rat intervertebral 
disc cells in vitro”, Spine, Vol. 18, (2003), pp. 1773-80. 
 
31 Davidson A.J., Postlethwait J.H., Yan Y.L., “Isolation of zebrafish gdf7 and comparative 
genetic mapping of genes belonging to the growth/differentiation factor 5, 6, 7 subgroup of the 
TGF-beta superfamily”, Genome Res, Vol. 9, (1999), pp. 121-9. 
 
32 Fu S.C., Wong Y.P., Chan B.P., “The roles of bone morphogenetic protein (BMP) 12 in 
stimulating the proliferation and matrix production of human patellar tendon fibroblasts”, Life 
Sci, Vol. 72, (2003), pp. 2965-74. 
 
33 Furuya K., Nifuji A., Rosen V. “Effects of GDF7/BMP12 on proliferation and alkaline 
phosphatase expression in rat osteoblastic osteosarcoma ROS 17/2.8 cells”, J Cell Biochem, 
Vol. 72, (1999), pp. 177-80. 
 
34 Lee K.J., Mendelsohn M., Jessell T.M., “Neuronal patterning by BMPs: a requirement for 
GDF7 in the generation of a discrete class of commissural interneurons in the mouse spinal 
cord”, Genes Dev, Vol. 12, (1998), pp. 3394-407. 
 
 
 128
 
35 Settle S., Marker P., Gurley K., “The BMP family member Gdf7 is required for seminal 
vesicle growth, branching morphogenesis, and cytodifferentiation”, Dev Biol, Vol. 234, 
(2001), pp. 138-50. 
 
36 Watakabe A., Fujita H., Hayashi M., “Growth/differentiation factor 7 is preferentially 
expressed in the primary motor area of the monkey neocortex”, J Neurochem, Vol. 76, (2001), 
pp. 1455-64. 
 
37 Lou J., Tu Y., Burns M., “BMP-12 gene transfer augmentation of lacerated tendon repair”, J 
Orthop Res, Vol. 19, (2001), pp. 1199-202. 
 
38 Wolfman N.M., Hattersley G., Cox K., “Ectopic induction of tendon and ligament in rats by 
growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family”, J Clin 
Invest, Vol. 100, (1997), pp. 321-30. 
 
39 Lou J., Tu Y., Ludwig F.J., “Effect of bone morphogenetic protein-12 gene transfer on 
mesenchymal progenitor cells”, Clin Orthop, Vol. 369, (1999), pp. 333-9. 
 
40 Maroudas A., Stockwell R.A., Nachemson A., Urban J., “Factors involved in the nutrition of 
the human lumbar intervertebral disc: cellularity and diffusion of glucose in vitro”, J. Anat. , 
Vol. 120, 1, (1975), pp.113-130. 
 
41 Holm, S.H.: “Nutritionof the Intervertebral Disc”, The Lumbar Spine, Ed by JN Weinstein and 
SW Wiesel. Philadelphia, W.B. Saunders Company, (1990), pp 244-259. 
 
42 Oegema T.R.: “Recent Advances in Understanding the Biochemistry of the Intervertebral 
Disc”, Disorders of the Lumbar Spine, Ed by Yizhar Floman. Aspen Publishers Inc. and 
Freund Publishing House Ltd., (1990), pp53-71. 
 
43 Horner H.A.M., Urban, J.P.G., “Effect of Nutrient Supply on the Viability of Cells from the 
Nucleus Pulpsus of the Intervertebral Disc”, Spine, (2001), Vol. 26, pp. 2543-2549. 
 
44 Bernick S., Cailliet R., “Vertebral End Plate Changes with Aging of Human Vertebrate”, 
Spine, (1982), Vol. 7, pp. 97-102. 
 
45 Holm S., Nachemson A., “Variations in the nutrition of the canine intervertebral disc induced 
by motion”, Spine, (1983), Vol. 8, pp. 866-874. 
 
46 Holm S., Selstam G., “Oxygen tension alterations in the intervertebral disc as a response to 
changes in the arterial blood”, Upsala J Med Sci, (1982), Vol. 87, pp. 163-174. 
 
47 Urban J.P.G., Holm S., Maroudas A., Nachemson A., “Nutrition of the intervertebral disc: An 
in vivo study of solute transport”. Clin Orthop, (1977), Vol. 129, pp. 101-114. 
 
 
 129
 
48 Holm S.H.: “Nutritional and Pathophysiologic Aspects of the Lumbar Intervertebral Disc”, 
The Lumbar Spine, Ed by JN Weinstein and SW Wiesel. Philadelphia, W.B. Saunders 
Company, (1996), pp 285-309.     
 
49 Holm S., Maroudas A., Urban J.P.G., Selstam G., Nachemson A., “Nutritionof the 
intervertebral disc: Solute transport and metabolism”, Conn Tiss Res, (1981), Vol. 8, pp. 101-
110. 
 
50 Corrigan B., Maitland G.D., Vertebral Muskeletal Disorders, Reed Educational and 
Professional Publishing Ltd, (1998), pp1-17. 
 
51 Urban J.P.G., Maroudas A.: The Measurement of Fixed Charged Density in the Intervertebral 
Disc. Biochim Biophys Acta , Vol. 586, (1988), pp. 166-178.  
 
52 Urban J.P.G., MacMullin J.F., “Swelling Pressure of the Intervertebral Disc: Influence of 
Proteoglycan and Collagen Contents”, Biorheology, Vol. 22, (1985), pp. 145. 
 
53 Johnston B., Bayliss M.T. The Large Proteoglycans of the Human Intervertebral Disc: 
Changes in their Biosynthesis and Structure with Age, Topography, and Pathology, Spine, Vol. 
20, (1995), pp. 674-684. 
 
54 Urban J., Holm S.H., Lipson S.J.: “Biochemistry”, The Lumbar Spine, Ed by JN Weinstein 
and SW Wiesel. Philadelphia, W.B. Saunders Company, (1990), pp 231-243. 
 
55 Voet D., Voet J.G., Pratt G., “Overview of Metabolism”, Fundamentals of Biochemistry, John 
Wiley & Sons, Inc., (2002), pp354-359. 
 
56 Voet D., Voet J.G., Pratt G., “Overview of Glycolysis”, Fundamentals of Biochemistry, John 
Wiley & Sons, Inc., (2002), pp383-406. 
 
57 Ishihara H., Urban J.P.G., Effects of Low Oxygen Concentrations and Metabolic Inhibitors on 
Proteoglycan and Protein Synthesis Rates in the Intervertebral Disc, Journal of Orthopaedic 
Research, Vol. 17, (1999), pp. 829-35.  
 
58 Hannallah D., Peterson B., Liebermann J.R., Fu F.H., Huard J., Gene Therapy in Orthopaedic 
Surgery, JBJS, Vol. 84-A(6), (2002), pp. 1046-1061.  
 
59 Anderson W.F., “Reviews: Human Gene Therapy”, Nature, Vol. 392, (1998), pp. 25-27. 
 
60 Li S., Huang L., Nonviral Gene Therapy: Promises and Challenges, Gene Therapy, Vol. 7, 
(2000), pp. 31-34.  
 
 
 130
 
61 Kwoh D.Y., Coffin C.C., Lollo C.P., Stabilization of Poly-L-Lysine/DNA Polyplexes for In-
vivo Gene Delivery to the Liver, Biochimica et Biophysica Acta, Vol. 1444(2), (1999), pp. 
171-190.  
 
62 Nishida K., Kang J.D., Suh J.K., Robbins P.D., Evans C.H., Gilbertson L.G., Adenovirus-
Mediated Gene Transfer to Nucleus Pulposus Cells: Implications for the Treatment of 
Intervertebral Disc Degeneration, Spine, Vol. 23, (1998), pp. 2437-43.  
 
63 Oshima H., Ishihara H., Urban J.P.G., Tsuji H., “The Use of Coccygeal Discs to Study 
Intervertebral Disc Metabolism”, Journal of Orthopaedic Research, Vol. 11, (1993), pp. 332-
338. 
 
64 Bayliss M.T., Urban J.P., Johnstone B., Holm S., In-vitro Method for Measuring Synthesis 
Rates in the Intervertebral Disc. J. Orthop Res., Vol. 4, (1986), pp10-17.  
 
65 Chiba K., Andersson G., Masuda K., Momohara S., Williams J.M., Thonar E., A New Culture 
System to study the Metabolism of the Intervertebral Disc In-Vitro, Spine, Vol. 23(17), (1998), 
pp. 1821-1827. 
 
66 Takegami K., Masude K., An H., A Novel Culture System for the Intervertebral Disc: an 
Organ with Endplates (Abstract), Orthopaedic Research Society, 47th Annual Meeting, San 
Francisco, CA, (2001).  
 
67 Chelberg M.K., Banks G.M., Geiger D.F., Oegema T.R., “Identification of heterogenous cell 
populations in normal human intervertebral disc”, J Anat, Vol. 186, (1995), pp. 43-53. 
 
68 Frisbie D.D., Kawack C.E., Trotter G.W., McIlwraith C.W., The Assessment of Chondrocyte 
Proteoglycan Metabolism using Molecular Sieve Column Chromatography as Compared to 
Three Commonly Utilized Techniques.  Osteoarthritis and Cartilage, Vol. 6, (1998), pp. 137-
145. 
 
69 Suzuki K., Oyama M., Faulcon L., “In-vivo Expression of Human Growth Hormone by 
Genetically Modified Murine Bone Marrow Stromal Cells and its Effect on the Cells In-vitro”, 
Cell Transplant, Vol. 9, (2000), pp. 319-27. 
 
70 Alberts B., Bray D., Lewis J., Raff M., Roberts K., Watson J., Molecular Biology of the Cell, 
Garland Publishing, (1994), p 143. 
 
71 Asai D.J., Wilson L., Matsudaira P.: Methods in Cell Biology, Antibodies in Cell Biology, 
Academic Press, (1993), Vol. 37.   
 
72 Sanes J.R., Rubenstein J.L.R., Nicolas J.F., Use of a recombinant Retrovirus to Study Post-
Implantation Cell Lineage in Mouse Embryos., EMBO J, Vol. 5, (1986), pp. 133-42. 
 
 
 131
 
73 Farndale R.W., Buttle D.J., Barrett A.J., Improved Quantitation and Discrimination of 
Sulphated Glycosaminoglycans by use of Dimethylmethylene Blue, Biochimica et Biophysica 
Acta, Vol. 883, (1986), pp. 173-177. 
 
74 Chiba K., Andersson G., Masuda K., Momohara S., Williams J., Thonar E., “A New Culture 
System to Study the Metabolism of the Intervertebral Disc In-Vitro”, Spine, Vol. 23, (1998), 
pp. 1821-1827. 
 
 132
